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Abbreviation 
Boc tert-butoxycarbonyl 
Bn benzyl 
Bu butyl 
DIPEA N-N-diisopropylethylamine 
DMF N-N-dimethylformamide 
EETs Epoxyeicosatrienoic acids 
Et ethyl 
GBM glomerular basement membrane 
HATU 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl uronium 
hexafluorophosphate 
HETE hydroxyeicosatetraenoic acid 
HPETE hydroperoxyeicosatetraenoic acid 
LDA lithium diisopropylamide 
Me methyl 
Ms mesyl 
PDB Protein Data Bank 
PG prostaglandin 
SAR structure–activity relationship 
SPR structure–property relationship 
sEH Soluble epoxide hydrolase 
SHR spontaneously hypertensive rat 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TX thromboxane 
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Chapter 1 
General introduction 
 
1) Arachidonate cascade as a therapeutic target 
Arachidnic acid is derived from a phospholipid and converted into a variety of fatty acids through the 
arachidonate cascade (Figure 1-1). Some of these fatty acids are involved in the control of body functions such as 
inflammation. Because of the important role of these fatty acids, enzymes and receptors involved in the 
arachidonate cascade have been identified as therapeutic targets. Cyclooxygenase has a key role in the production 
of prostaglandins. Some cyclooxygenase inhibitors (e.g., aspirin and diclofenac) are marketed as therapeutic 
agents for treatment of pain and inflammation. Leukotrienes are derived from metabolism of arachidonic acid by 
lipoxygenase (LOX). Leukotriene receptor antagonists (e.g., pranlukast) have been used for treatment of asthma 
and seasonal allergies. 
Arachidonic acid
LipoxygenaseCyclooxygenaseCYP
Esterified arachidonic acid
Phospholipase A
PGG2
PGH2
TXA2PGI2 Prostaglandins
HPETEs
5-, 8-, 12-, 15-HETEs Leukotrienes
HETEs
EETs
sEH
DHETs
 
Figure 1-1. Major pathways of the arachidonate cascade. 
 2 
 
 
2) Soluble epoxide hydrolase 
Epoxyeicosatrienoic acids (EETs) are produced by epoxidation of arachidonic acid by CYP2J and CYP2C of the 
cytochrome P450 (CYP) superfamily (Figure 1-1). EETs exhibit physiologically beneficial effects such as 
vasodilatation, vasoprotection, and anti-inflammation. Soluble epoxide hydrolase (sEH), which is located in 
mainly liver, kidney, and vascular tissue
1,2
, converts EETs to dihydroxyeicosatrienoic acids (DHETs)
 3
. sEH 
inhibition produces effects expected from an increase in EETs level. 
 
3) Treatment of hypertension with sEH inhibitors 
Renal sEH expression is upregulated in angiotensin II hypertensive rat
4
 and spontaneously hypertensive rat 
(SHR),
5
 but not in normotensive rat. Several preclinical studies have indicated that sEH inhibitors significantly 
reduce blood pressure in angiotensin II hypertensive rat and SHR, but have no effect in normotensive rat. These 
findings suggest that sEH inhibitors have potential use for treating hypertension without causing any hypotensive 
side effects. 
 
4) Treatment of chronic kidney disease with sEH inhibitors 
Chronic kidney disease is defined as abnormalities of kidney structure or function, present for >3 months, with 
implications for health. People with end-stage kidney disease (ESKD) (known as stage 5 chronic kidney disease) 
need to be treated with dialysis or translant.
6
 These treatments lower patients’ quality of life, so chronic kidney 
disease should be treated from an early stage. The standard of care for patients with chronic kidney disease is 
administration of blood pressure-lowering drugs such as angiotensin-converting enzyme inhibitors or angiotensin 
II receptor antagonists, both of which slow down the progression of chronic kidney disease. However, no drugs 
can cure or reverse the disease. According to a recent report,
7a
 sEH in proximal tubular cells is upregulated in 
chronic proteinuric kidney diseases. According to that study, 
1-(1-methylsulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)urea reduces long-term elevated serum 
creatinine levels, interstitial inflammation, fibrosis, and α-smooth muscle actin expression in adriamycin-induced 
 3 
 
nephropathic mice. These findings suggest that sEH inhibitors have potential use in treating chronic proteinuric 
kidney diseases.
 7
 
 
5) sEH inhibitors 
The catalytic pocket of sEH consists of Tyr381, Tyr465, and Asp333, which are responsible for the enzymatic 
activity. X-ray crystal structures have been reported for sEH inhibitors bound to sEH (e.g., Protein Data Bank 
(PDB) code: 1VJ5). The structures suggested that amide or urea derivatives may bind to the catalytic pocket via 
hydrogen bonds between the amide or urea carbonyl oxygen and Tyr381 or Tyr465, and between the urea or amide 
NH and Asp333 (Figure 1-2).
8
  
 
 
Figure 1-2. Transition state for epoxide opening catalyzed by sEH. (left) and general binding mode of a 
dialkylurea to sEH (right)  
 
Morisseau et al. reported that 1,3-disubstituted ureas with a adamantan-1-yl group are potent sEH inhibitors (an 
example is AUDA; Figure 1-3).
9
 In subsequent studies, a number of sEH inhibitors containing amide, urea, and 
isoxazole moieties have been identified.
10,11
 The sEH inhibitor AR9281 (Figure 1-3) has good oral bioavailability, 
antihypertensive effects in SHR, and antidiabetic effects in diet-induced obesity mouse. AR9281 was advanced to 
human clinical trial involving obese patients with stage 1 hypertension and impaired glucose tolerance. A variety 
 4 
 
of cyclic amine-based trisubstituted ureas that are potent sEH inhibitors have also been reported (Figure 1-3).
12
 
Although a number of sEH inhibitors have potent in vitro activity, only a few sEH inhibitors have in vivo efficacy. 
Oral administration of some sEH inhibitors failed to reduce blood pressure in SHR but elevated EET levels in the 
kidney.
12
 Thus, development of sEH inhibitors with in vivo potency was thought to be a challenging task. 
 
 
Figure 1-3. Examples of reported sEH inhibitors. 
 
6) Goal of this research 
The in vivo efficacy of sEH inhibitors remains unclear; nevertheless, considering the in vivo potency of some 
sEH inhibitors (e.g., AR9281, Figure 1-2) and the beneficial effects described above, our laboratory was 
motivated to embark on a search for novel sEH inhibitors. The goal of this research was to identify orally active 
sEH inhibitors for the treatment of hypertension and chronic kidney disease. 
 
7) Plan for developing orally active sEH inhibitors 
In addition to referring to the reports mentioned above, I planned to utilize docking studies for the design of 
novel sEH inhibitors. A docking study is a powerful tool in medicinal chemistry, and predicts the binding 
orientation of a ligand to a target protein. Docking studies help medicinal chemists design new ligands with higher 
affinity to the target protein. If a docking study shows that around the ligand binding pocket of the target protein 
there are any amino acid residues that might form hydrogen bonds with a ligand, installing hydrogen bond donors 
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or acceptors in the parent ligand could improve the binding affinity. X-ray crystal structures have been reported 
for human sEH (e.g., PDB code: 1VJ5) and mouse sEH (e.g., PDB code: 1EK1) bound to sEH inhibitors. 
However, there is no X-ray crystal structure of rat sEH. A docking study using these reported X-ray crystal 
structures could facilitate the discovery of sEH inhibitors. 
In the development of orally active small molecule drugs, scientists are often faced with difficult problems. 
Some problems in drug discovery relate to in vitro biological activity and pharmacokinetics. With respect to in 
vitro biological activity, it is often necessary to identify compounds that have activity toward a target protein in 
both humans and animals, because it is necessary to extrapolate efficacy for human diseases from biological tests 
using animal models of target diseases. Pharmacokinetic profiles, which relate to efficacy, are described with 
parameters such as oral bioavailability, clearance (CL), biological half-life (t1/2), maximum drug concentration 
(Cmax), area under the blood concentration-time curve (AUC), and volume of distribution (Vd). The oral 
bioavailability of a compound depends on its lipid membrane permeability, stability to CYP-mediated metabolism, 
solubility in gastric and intestinal fluids and carrier-mediated transport. Lipinski’s rule of five describes the 
likelihood that a drug will be orally active.
13
 This rule says that, generally speaking, an orally active drug has no 
more than 5 hydrogen bond donors, no more than 10 hydrogen bond acceptors, a molecular mass of less than 500 
Da, and an octanol-water partition coefficient log P no greater than 5. Because it would be impractical to evaluate 
the pharmacokinetic profiles and in vivo efficacies of all the compounds that couple possibly be synthesized, I 
planned to search for compounds that satisfy Lipinski’s rule and that have in vitro inhibitory activity against 
human, mouse, and rat sEH; solubility in biologically relevant medium; and stability to CYP-mediated 
metabolism. The pharmacokinetic profiles and in vivo efficacies of the identified compounds were then evaluated.  
Following this plan, the search for novel sEH inhibitors was started. Details of particular studies are given in 
Chapter 2-5. 
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Chapter 2 
Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted ureas as 
highly potent soluble epoxide hydrolase inhibitors and orally active 
drug candidates for the treatment of hypertension 
 
Abstract: The identification of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble 
epoxide hydrolase (sEH) inhibitors and orally active agents for treating hypertension is described. Docking studies 
using human and mouse sEH X-ray crystal structures revealed steric hindrance around the side chain of Phe406 of 
mouse sEH. The trifluoromethyl moiety (II-21) was replaced with a trifluoromethoxy moiety (II-22) to prevent steric 
clash, and improved mouse sEH inhibitory activity was observed. The oral administration of II-22, II-30, and II-47 at a 
dose of 30 mg/kg reduced blood pressure in spontaneously hypertensive rat, but had little effect on blood pressure in 
normotensive rat. 
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Introduction 
 
Motivated by the expected beneficial effects of sEH inhibitors as described in Chapter 1, I began to search for 
sEH inhibitors to serve as agents for treating hypertension without causing hypotensive side effects.  
 
Design 
 
The linear structures of epoxyeicosatrienoic acids and the reported X-ray crystal structural analysis of sEH 
inhibitors bound to sEH suggest an elongated cylindrical hydrophobic pocket around the catalytic site of sEH. 
Amide and urea derivatives with linear hydrophobic substituent were expected to be favored as ligands for 
catalytic pocket of sEH. Recently, there has been much interest in spirocyclic diamine scaffolds in medicinal 
chemistry,
1
 leading to studies on the synthesis and structure–activity relationship (SAR) of diazaspirocyclic 
compounds. The reason why I focused on these scaffolds is that their rigidity may contribute to efficient 
interaction with target proteins. Because of this feature, the diazaspiro-based ureas for use as sEH inhibitors were 
designed (Figure 2-1). I aimed to design the sEH inhibitors following Lipinski’s rule (see Chapter 1-6) in order to 
discover orally active drugs. 
 
 
Figure 2-1. Example of spirocyclic diamine scaffold and sEH inhibitor design. 
 
Chemistry 
 
 The starting materials II-5 and II-12 were synthesized according to the literature.
2
 The synthesis of 
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2,8-diazaspiro[4.5]decane scaffold II-5 is shown in Scheme 2-1. Ester II-1 was deprotonated with LDA and 
alkylated. II-2 was treated with benzylamine affording II-3. Deprotection of the Boc group using HCl led to II-4. 
Reduction of imide II-4 was carried out with LiAlH4 providing II-5. The synthesis of 3,9-diazaspiro[5.5]undecane 
scaffold II-12 is shown in Scheme 2-2. II-6 was treated with ethyl 2-cyanoacetate in basic media, and then the 
product was treated with H2SO4 to obtain diester II-7. II-8 was obtained by reducing diester II-7 with LiAlH4. 
Removing the benzyl group and protecting an amine with a Boc group through Pd(OH)2-catalyzed hydrogenation 
in the presence of (Boc)2O afforded II-9. Dimesylation of II-9 was carried out, and II-10 was obtained. II-10 was 
treated with benzylamine to obtain II-11. Removal of the Boc group in II-11 with HCl gave II-12. The general 
procedure for synthesizing the series of target compounds is shown in Scheme 2-3. II-13-A was formed by 
treating II-5 or II-12 with isocyanate or with carbamate prepared from p-nitrophenyl chloroformate and amine. 
Removal of the benzyl protecting groups by Pd(OH)2-catalyzed hydrogenation provided II-14-A. Then, 
condensation with carboxylic acid afforded the target compounds. Otherwise, II-5 or II-12 was condensed with 
carboxylic acid to produce II-13-B. Removal of the benzyl protecting groups by Pd(OH)2-catalyzed 
hydrogenation provided II-14-B. Then, the target compounds were formed by treating II-14-B with isocyanate or 
with carbamate prepared from p-nitrophenyl chloroformate and amine. 
 
 
Scheme 2-1. Synthesis of 2,8-diazaspiro[4.5]decane scaffold II-5. 
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Scheme 2-2. Synthesis of 3,9-diazaspiro[5.5]undecane scaffold II-12. 
 
 
Scheme 2-3. Synthesis of diazaspiro-based ureas (x = 1, 2; y = 1, 2). 
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Results and discussion 
 
The diazaspiro-based urea derivatives listed in Tables 2-1 to 2-6 had 1 or 2 hydrogen bond donors, 4-9 hydrogen 
bond acceptors, molecular mass of 424-501 Da, and an octanol-water partition coefficient log P of 0.75-4.15. 
These derivatives almost satisfied Lipinski’s rule. 
SAR studies of various diazaspiro scaffolds were performed (see Table 2-1). The adamantan-1-yl group was 
selected as the left-hand substituent while 2,6-difluorobenzoyl was as the right-hand-side substituent. The highest 
inhibitory activity against human sEH was observed for the 2,8-diazaspiro[4.5]decane framework (II-15), which 
was therefore utilized in subsequent SAR and structure–property relationship (SPR) studies. 
 
Table 2-1. SARs of diazaspiro scaffolds. 
Structure Compound 
Human sEH 
IC50 (nM) 
 
 
II-15 175.6 
 
 
II-16 >200 
 
 II-17 466.3 
 
SAR and SPR studies of the left-hand side were performed (Table 2-2). Replacing the adamantan-1-yl group of 
II-15 with 4-methoxyphenyl (II-18) slightly improved inhibitory activity against human sEH. The 4-cyano 
derivative II-19 was a more potent human sEH inhibitor than II-18, but the inhibitory activity of II-19 against 
mouse sEH was lower. 4-Chloro derivative II-20 showed high inhibitory activity against human sEH, but only 
modest inhibitory activity against mouse sEH. Introduction of a trifluoromethyl moiety at the 4-position led to 
excellent human sEH inhibitory activity (II-21). 
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Table 2-2. SARs and SPRs of the left-hand side with 4-substituted phenyl. 
 
R Compound 
Human sEH 
IC50(nM) 
Murine sEH 
IC50(nM) 
Rat sEH 
IC50(nM) 
Solubility 
JP1
b
  
(g/mL) 
Solubility 
JP2
c
 
(g/mL) 
Microsomal 
stability
a
 
 
 
II-15 175.6 N.D. N.D. 80 80 0.485 
 
 
II-18 151.6 731.0 N.D. N.D. N.D. N.D. 
 
 
II-19 51.7 1445.0 N.D. 77 77 0.022 
 
 
II-20 6.7 489.0 N.D. 71 64 N.D. 
 
 
II-21 0.3 228.0 6.1 23 21 0.043 
a
 Units: mL/min/mg protein. 
b
 Simulated gastric fluid compliant with the Japanese Pharmacopoeia 
c
 Simulated intestinal fluid compliant with the Japanese Pharmacopoeia 
N.D.: Not determined. 
 
However, a major challenge that arose was dealing with the approximately 800-fold difference between the 
mouse and human sEH inhibitory activities. For this reason, I attempted to design derivatives with sufficient 
mouse sEH inhibitory activity for evaluating efficacy in a mouse disease model. Also, to elucidate the difference 
in inhibitory activity between human and mouse sEHs for II-21, docking studies of human and mouse sEHs with 
II-21 were performed using X-ray crystal structures (Figure 2-2). The results revealed that the trifluoromethyl 
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moiety of II-21 sterically clashes with the side chain of Phe406 in mouse sEH, which is replaced with Leu406 in 
human sEH, and the oxygen atom of the urea moiety of II-21 is bound to Tyr381, Tyr465, and Asp333 in the 
catalytic pocket of both sEHs. This steric hindrance caused the lower binding affinity of II-21 to mouse sEH than 
to human sEH. To resolve this steric hindrance, I envisioned inserting an oxygen atom between the aromatic ring 
and the trifluoromethyl functional group to keep the trifluoromethyl moiety of II-21 apart from the side chain of 
Phe406 in mouse sEH and I designed II-22. A docking study of 4-trifluoromethoxy derivative II-22 with mouse 
sEH suggested that II-22 should bind to the catalytic pocket of mouse sEH without steric hindrance (Figure 2-3). 
In line with my expectation, II-22 was found to have sufficient inhibitory activity in human, rat, and mouse sEHs 
(Table 2-3). On the other hand, the insertion of the single methylene linkage resulted in decreased inhibitory 
activities of both human and mouse sEHs (II-23). 
 
 
 
 
 
 
Figure 2-2. Docking studies of human sEH (left; PDB code: 1VJ5) and mouse sEH (right; PDB code: 1EK1) with 
II-21 (depicted by space filling model). The residues Leu406 in human sEH and Phe406 in mouse sEH are shown 
as gray space filling models. 
 
 
 
 
 
Figure 2-3. a) Structure of II-22. b) Docking studies of murine sEH (PDB code: 1EK1) with II-22 (depicted by 
space filling model). The residue Phe406 was highlighted by space filling model in gray. 
Leu406 
Asp333 
Tyr381 
Tyr465 
Asp333 
Tyr381 
Tyr465 
Phe406 
Phe406 
b) 
a) 
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Table 2-3. SARs and SPRs of the left-hand side with 4-substituted phenyl. 
 
R Compound 
Human sEH 
IC50(nM) 
Murine sEH 
IC50(nM) 
Rat sEH 
IC50(nM) 
Solubility 
JP1
b
  
(g/mL) 
Solubility 
JP2
c
 
(g/mL) 
Microsomal 
stability
a
 
 
 
II-21 0.3 228.0 6.1 23 21 0.043 
 
 
II-22 0.4 25.7 4.5 24 21 0.000 
 
 
II-23 5.7 97.5 N.D. 60 54 0.003 
a
 Units: mL/min/mg protein. 
b
 Simulated gastric fluid compliant with the Japanese Pharmacopoeia 
c
 Simulated intestinal fluid compliant with the Japanese Pharmacopoeia 
N.D.: Not determined. 
 
I speculated that 3-substituted phenyl derivatives would not have the steric hindrance described above and 
designed II-24 and II-25 (see Table 2-4). The 3-substituted phenyl derivatives II-24 and II-25 were also examined. 
Compared with II-21, the 3-trifluoromethyl derivative II-24 showed improved inhibitory activity against mouse 
sEH, suggesting that substitution at the 3-position alleviated steric hindrance, leading to the enhanced inhibitory 
activity. However, substitution with a bulky group (II-25) was found to be ineffective in alleviating the steric 
hindrance. 
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Table 2-4. SARs and SPRs of the left-hand side with 3-substituted phenyl. 
 
R Compound 
Human sEH 
IC50(nM) 
Murine sEH 
IC50(nM) 
Rat sEH 
IC50(nM) 
Solubility 
JP1
b
  
(g/mL) 
Solubility 
JP2
c
 
(g/mL) 
Microsomal 
stability
a
 
 
 
II-21 0.3 228.0 6.1 23 21 0.043 
 
 
II-24 16.1 72.7 N.D. 26 23 0.034 
 
 
II-25 35.3 439.0 N.D. N.D. N.D. N.D. 
a
 Units: mL/min/mg protein. 
b
 Simulated gastric fluid compliant with the Japanese Pharmacopoeia 
c
 Simulated intestinal fluid compliant with the Japanese Pharmacopoeia 
N.D.: Not determined. 
 
Considering the study results in Table 2-4, I envisioned that substitution at the 3-position of II-20 would enhance 
the murine sEH inhibitory activity of II-20. 4-Chloro derivatives with additional substituents at the 3-position 
(II-26 to II-28) were also studied and found to exhibit inhibitory activity against mouse sEH which was 
approximately 8-fold that of 4-chloro II-20. In contrast, compounds with substituents at the 2-position (II-29) 
showed sEH inhibitory activity much lower than that of II-20 (see Table 2-5). Thus, I speculate that the 
substituent at the 2-position affects the interaction between the urea moiety and the amino acid residues in the 
hydrolase catalytic pocket. From the above results, the derivative with a 4-trifluoromethoxyphenyl substituent in 
the left-hand moiety (II-22) was selected for in vivo studies. It showed good metabolic stability and tolerable 
solubility. 
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Table 2-5. SARs and SPRs of the left-hand side with 3,4-substituted phenyl. 
 
R Compound 
Human sEH 
IC50(nM) 
Murine sEH 
IC50(nM) 
Rat sEH 
IC50(nM) 
Solubility 
JP1
b
  
(g/mL) 
Solubility 
JP2
c
 
(g/mL) 
Microsomal 
stability
a
 
 
 
II-20 6.7 489.0 N.D. 71 64 N.D. 
 
 
II-24 16.1 72.7 N.D. 26 23 0.034 
 
 
II-26 1.1 25.2 N.D. 4 4 N.D. 
 
 
II-27 3.5 61.0 N.D. 8 7 0.069 
 
 
II-28 3.4 31.6 N.D. 24 21 0.079 
 
 
II-29 115.0 1112.0 N.D. N.D. N.D. N.D. 
a
 Units: mL/min/mg protein. 
b
 Simulated gastric fluid compliant with the Japanese Pharmacopoeia 
c
 Simulated intestinal fluid compliant with the Japanese Pharmacopoeia 
N.D.: Not determined. 
 
Finally, the SAR and SPR of the right-hand side (see Table 2-6) were studied in order to improve the solubility of 
II-22. The solubility was slightly improved by altering the substituent of the phenyl ring on the right-hand side 
(II-30 to II-32). The replacement with heteroaromatic rings (II-33 to II-39) and alkyl groups (II-40 to II-51) also 
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gave good solubility. In terms of sEH inhibitory activity, benzamides (II-30 to II-32), heteroaromatic amides 
(II-33 to II-39), and alkyl amides (II-40 to II-51) were well tolerated for human and rat sEH, but this was not the 
case in mouse sEH. The comparison between II-30 and II-31 revealed that a hydroxy group introduced onto 
benzamide enhanced mouse sEH inhibitory activity. II-35 showed potency for human sEH inhibition 573-fold that 
for mouse sEH inhibition. Compared with II-22, alkyl amides II-42, II-49, and II-51 were more potent mouse 
sEH inhibitors, but were labile to CYP-mediated metabolism. 
 
Table 2-6. SARs and SPRs of the right-hand side. 
 
 
R’ Compound 
Human sEH 
IC50(nM) 
Murine sEH 
IC50(nM) 
Rat sEH 
IC50(nM) 
Solubility 
JP1
 b
  
(g/mL) 
Solubility 
JP2
 c
  
(g/mL) 
Microsomal 
stability
a
 
 
 
II-22 0.4 25.7 4.5 24 21 0.000 
 
 
II-30 0.7 40.6 5.3 56 47 0.021 
 
 
II-31 0.2 11.0 4.1 38 35 0.044 
 
 
II-32 0.3 N.D. 5.2 35 30 0.01 
 
 
II-33 0.2 64.5 6.6 94 58 0.057 
 
 
II-34 0.8 91.5 22.2 92 86 0.001 
 
 
II-35 0.4 229.0 11.9 87 86 0.008 
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Table 2-6. SARs and SPRs of the right-hand side. 
R’ Compound 
Human sEH 
IC50(nM) 
Murine sEH 
IC50(nM) 
Rat sEH 
IC50(nM) 
Solubility 
JP1
 b
  
(g/mL) 
Solubility 
JP2
 c
  
(g/mL) 
Microsomal 
stability
a
 
 
 
II-36 0.4 N.D. 5.3 82 80 0.058 
 
 
II-37 0.2 67.4 11.7 86 82 0.000 
 
 
II-38 0.5 40.6 N.D. 79 72 0.128 
 
 
II-39 0.9 N.D. 9.5 78 75 0.019 
 
 
II-40 2.8 108.0 N.D. 83 81 N.D. 
 
 
II-41 3.0 116.0 N.D. 85 85 N.D. 
 
 
II-42 0.7 21.5 9.0 64 60 0.314 
 
 
II-43 1.2 N.D. 22.4 87 86 0.020 
 
 
II-44 0.3 N.D. 4.7 88 88 0.007 
 
 
II-45 0.5 N.D. 15.8 77 78 0.019 
 
 
II-46 1.3 83.8 13 77 77 0.054 
 
 
II-47 0.6 N.D. 6.4 73 74 0.021 
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Table 2-6. SARs and SPRs of the right-hand side. 
R’ Compound 
Human sEH 
IC50(nM) 
Murine sEH 
IC50(nM) 
Rat sEH 
IC50(nM) 
Solubility 
JP1
 b
  
(g/mL) 
Solubility 
JP2
 c
  
(g/mL) 
Microsomal 
stability
a
 
 
 
II-48 0.6 65.5 9.4 75 75 0.015 
 
 
II-49 0.3 13.1 N.D. 79 78 0.089 
 
 
II-50 0.8 64.3 N.D. 74 75 0.195 
 
 
II-51 0.4 21.7 N.D. 37 33 0.483 
a
 Units: mL/min/mg protein. 
b
 Simulated gastric fluid compliant with the Japanese Pharmacopoeia. 
c
 Simulated intestinal fluid compliant with the Japanese Pharmacopoeia. 
N.D.: Not determined. 
 
In the next study, I investigated the efficacy of II-22, II-30, and II-47 at inducing a hypotensive effect in 
spontaneously hypertensive rat (SHR) and normotensive rat. These derivatives were selected based on other 
biological tests The oral administration of these compounds at a dose of 30 mg/kg reduced blood pressure in SHR 
(Figure 2-4, top), but had little effect on blood pressure in normotensive rat (Figure 2-4, bottom).  
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Figure 2-4. Hypotensive effect of II-22, II-30, and II-47 in WKY rat. Mean blood pressure (MBP) change from 
baseline (mmHg) for II-22, II-30, and II-47 (30 mg/kg, po) in SHR (top) and normotensive rat (bottom) at 6 h 
after administration. Solvent: methylcellulose/tween. 
 
Note that no reduction in blood pressure has been observed in SHR after the administration of several sEH 
inhibitors.
3
 The Doris group has reported that several haplotypes of SHR are insensitive to sEH inhibitors,
4
 but the 
reason for the difference between their results and mine is currently unclear. 
 
Summary 
 
In summary, 2,8-diazaspiro[4.5]decane-based trisubstituted ureas were identified as highly potent sEH inhibitors 
and orally active agents for treating hypertension. In SAR studies on its left-hand side, the potent human sEH 
inhibitor II-21 was found to be a weak mouse sEH inhibitor. Docking studies of human and mouse sEHs using 
X-ray crystal structures revealed steric hindrance around the side chain of Phe406 in mouse sEH with II-21. From 
the results of this study, I adopted a trifluoromethoxy moiety instead of a trifluoromethyl moiety in order to 
prevent such steric hindrance and, in this way, succeeded at improving the mouse sEH inhibitory activity. In terms 
of inhibitory activity, various substituents on the right-hand side were well tolerated in human and rat sEHs, and 
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the solubility of II-22 was improved by changing the substituent on the right-hand side. Oral administration of 
II-22, II-30, and II-47 at a dose of 30 mg/kg reduced blood pressure in SHR, but had little effect on blood 
pressure in the normotensive rat. 
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Experimental Section 
General Information 
All reagents and solvents were of commercial quality and were used without further purification unless 
otherwise noted. 
1
H NMR spectra were recorded on JNM-AL400 at 400 MHz and are referenced to an internal 
standard of tetramethylsilane (TMS, 0). Chemical shifts are given in ppm. Coupling constants (J) are given in 
Hz. Multiplicities are abbreviated as singlet (s), doublet (d), triplet (t), quartet (q), doublet‐doublet (dd), 
multiplet (m), and broad (br). Mass spectra were recorded with electron-spray ionization (ESI) on a Waters 
ZQ-2000. Thin layer chromatography was performed using Merck Kieselgel 60 F254 plates (0.25 mm). 
Compounds were visualized by UV-light at 254 nm and color reagents. Flash chromatography was performed 
using Yamazen
 
HI-FLASH COLUMNS (Particle Size：40 m). Solvents were removed by rotary evaporation. 
 
1-tert-Butyl 4-ethyl 4-(2-methoxy-2-oxoethyl)piperidine-1,4-dicarboxylate (II-2). 
 Under argon atmosphere, n-BuLi (10.9 ml, 17.1 mmol, 1.57 M in-n-hexane) was added to a solution of 
diisopropylamine (2.44 ml, 17.1 mmol) in THF (30 ml) cooled at -78 C. The solution was stirred at -78 C for 30 
min. A solution of 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate (II-1) (4.0 g, 15.5 mmol) in THF (15 ml) was 
added, and the solution was stirred at -78 C for 1 h. Methyl 2-bromoacetate (2.24 ml, 24.3 mmol) was added, and 
the solution was stirred at -78 C for 1 h. The solution was warmed up to rt and stirred for 18 h. A saturated 
aqueous solution of NH4Cl was added, and the aqueous layer was extracted with ethyl acetate. The combined 
organic layers were washed with brine, dried over Na2SO4, filtered and evaporated under reduced pressure. The 
crude product was purified by silica gel flash chromatography (ethyl acetate-n-hexane) to afford II-2 in 16% 
yield. 
1
H NMR (CDCl3, 400MHz)  1.28 (3H, t, J = 6.8 Hz), 1.46 (9H, s), 1.50-1.56 (2H, m), 2.07-2.13 (2H, m), 2.61 
(2H, brs), 3.13-3.22 (2H, m), 3.66 (3H, s), 3.68- 3.72 (2H, m), 4.21 (2H, q, J = 6.8 Hz). 
MS (ESI) m/z 330 [M+H]
+
. 
 
tert-Butyl 2-benzyl-1,3-dioxo-2,8-diazaspiro[4.5]decane-8-carboxylate (II-3). 
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A mixture of 1-tert-butyl 4-ethyl 4-(2-methoxy-2-oxoethyl)piperidine-1,4-dicarboxylate (II-2) (817 mg, 2.48 
mmol) and benzylamine (2.7 ml, 24.8 mmol) was stirred at 160 C for 18 h. 3 M aqueous HCl was added, and the 
aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried 
over Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by silica gel flash 
chromatography (ethyl acetate-n-hexane) to afford II-3 in 58% yield. 
1
H NMR (CDCl3, 400MHz)  1.46 (9H, m), 1.92-2.04 (2H, m), 2.58 (2H, m), 2.92-3.01 (2H, m), 4.01 (2H, brs), 
4.64 (2H, s), 7.28-7.34 (5H, m). 
MS (ESI) m/z 359 [M+H]
+
. 
 
2-Benzyl-2,8-diazaspiro[4.5]decane-1,3-dione (II-4). 
To a solution of tert-butyl 2-benzyl-1,3-dioxo-2,8-diazaspiro[4.5]decane-8-carboxylate (II-3) (512 mg, 1.4
3 mmol) in methanol (4 ml) was added HCl in methanol (20%, 6 ml). The solution was stirred at rt fo
r 4 h. The solution was neutralized with 1 M aqueous NaOH, and the aqueous layer was extracted with
 dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
evaporated under reduced pressure to afford  II-4  in 88% yield. 
1
H NMR (CDCl3, 400MHz)  1.42-1.46 (2H, m), 1.93-2.01 (2H, m), 2.60 (2H, s), 2.65-2.71 (2H, m), 3.10-3.15 
(2H, m), 4.64 (2H, s), 7.28-7.34 (5H, s). 
MS (ESI) m/z 259 [M+H]
+
. 
 
2-Benzyl-2,8-diazaspiro[4.5]decane (II-5). 
To a solution of 2-benzyl-2,8-diazaspiro[4.5]decane-1,3-dione (II-4) (280 mg, 1.084 mmol) in THF (5 m
l) was added LiAlH4 (206 mg, 5.42 mmol). The mixture was stirred at rt for 4 h. Water was added, an
d the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with bri
ne, dried over Na2SO4, filtered and evaporated under reduced pressure to afford II-5 in 87% yield. 
1
H NMR (CDCl3, 400MHz)  1.50-1.53 (4H, m), 1.62-1.66 (2H, m), 2.37 (2H, s), 2.58 (2H, t, J = 6.8
 Hz), 2.74-2.78 (4H, m), 3.58 (2H, s), 7.30-7.38 (5H, m). 
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MS (ESI) m/z 231 [M+H]
+
. 
 
(2-Benzyl-2,8-diazaspiro[4.5]decan-8-yl)(2,6-difluorophenyl)methanone (II-13B1). 
To a solution of 2-benzyl-2,8-diazaspiro[4.5]decane (120 mg, 0.52 mmol) and 2,6-difluorobenzoyl chlorid
e (76 μl, 0.6 mmol) in dichloromethane (3 ml) was added DIPEA (145 μl, 1.04 mmol). The solution wa
s stirred at rt for 2 h. Water was added, and the aqueous layer was extracted with dichloromethane. The
 combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated under redu
ced pressure. The crude product was purified by silica gel flash chromatography (ethyl acetate-n-hexane) 
to afford II-13B1 in 76% yield. 
1
H NMR (CDCl3, 400MHz)  1.55-1.72 (6H, m), 2.38 (1H, d, J = 9.2 Hz), 2.43 (1H, d, J = 9.2 Hz), 2.56-2.65 
(2H, m), 3.20-3.24 (2H, m), 3.55 (1H, d, J = 13.6 Hz), 3.62 (1H, d, J = 13.6 Hz), 3.65-3.72 (1H, m), 3.77-3.82 
(1H, m) , 6.91-6.95 (2H, m) , 7.22-7.36 (6H, m). 
MS (ESI) m/z 371 [M+H]
+
. 
 
(2,6-Difluorophenyl)(2,8-diazaspiro[4.5]decan-8-yl)methanone (II-14B1). 
To a solution of (2-benzyl-2,8-diazaspiro[4.5]decan-8-yl)(2,6-difluorophenyl)methanone (II-13B1) (147 mg,
 0.04 mmol) in methanol (3 ml) was added 10% Pd(OH)2 on carbon (45 mg). Under hydrogen atmosph
ere, the mixture was stirred at rt for 18 h and filtered through a pad of Celite. The solvent was remove
d under reduced pressure to afford II-14B1 in quantitative yield. 
1
H NMR (CDCl3, 400MHz)  1.60-1.80 (4H, m), 1.95-2.02 (2H, m), 3.12-3.26 (1H, m), 3.29-3.34 (2H, m), 
3.42-3.49 (3H, m), 3.76-3.84 (2H, m), 6.92-7.02 (2H, m), 7.34-7.38 (1H, m). 
MS (ESI) m/z 281 [M+H]
+
. 
 
N-(Adamantan-1-yl)-8-(2,6-difluorobenzoyl)-2,8-diazaspiro[4.5]decane-2-carboxamide (II-15). 
To a solution of (2,6-difluorophenyl)(2,8-diazaspiro[4.5]decan-8-yl)methanone (50 mg, 0.18 mmol) and ad
amantan-1-yl isocyanate (40 mg, 0.21 mmol) in dichloromethane (1 ml) was added DIPEA (50 μl, 0.29 
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mmol). The solution was stirred at rt for 16 h. Water was added, and the aqueous layer was extracted 
with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered 
and evaporated under reduced pressure. The crude product was purified by silica gel flash chromatograph
y (ethyl acetate-n-hexane) to afford II-15 in 81% yield. 
1
H NMR (CDCl3, 400 MHz)  1.50-1.63 (2H, m), 1.64-1.75 (8H, m), 1.80-1.88 (2H, m), 1.98-2.01 (6H, m), 
2.05-2.12 (3H, m), 3.20-3.42 (6H, m), 3.62-3.73 (1H, m), 3.90-3.99 (2H, m), 6.91-7.00 (2H, m), 7.26-7.41 (1H, 
m). 
MS (ESI) m/z 458 [M+H]
+
. 
 
N-((adamantan-1-yl)-2-benzyl-2,8-diazaspiro[4.5]decane-8-carboxamide (II-13-A1). 
Starting from 2-benzyl-2,8-diazaspiro[4.5]decane (II-5) the title compound was obtained following the pr
ocedure described for-N-(Adamantan-1-yl)-8-(2,6-difluorobenzoyl)-2,8-diazaspiro[4.5]decane-2-carboxamide (I
I-15) in 51% yield. 
1
H NMR (CDCl3, 400 MHz)  1.53-1.56 (4H, m), 1.62-1.68 (9H, m), 1.96-1.98 (6H, m), 2.06 (3H, brs), 2.37 (2H, 
s), 2.60 (2H, t, J = 6.8 Hz), 3.20-3.25 (4H, m), 3.58 (2H, s), 4.18 (1H, brs) , 7.23-7.31 (5H, m). 
MS (ESI) m/z 408 [M+H]
+
. 
 
N-(adamantan-1-yl)-2-(2,6-difluorobenzoyl)-2,8-diazaspiro[4.5]decane-8-carboxamide (II-16). 
To a solution of N-((adamantan-1-yl)-2-benzyl-2,8-diazaspiro[4.5]decane-8-carboxamide (II-13-A1) (22 mg､
0.054 mmol) in methanol (3 ml) was added 10% Pd(OH)2 on carbon (22 mg). Under hydrogen atmosph
ere, the solution was stirred at rt for 18 h and filtered through a pad of Celite. The solvent was remove
d under reduced pressure. To a solution of the resulting residue and 2,6-difluorobenzoyl chloride (7.4 μl,
 0.06 mmol) in dichloromethane (0.5 ml) was added DIPEA (14 μl, 0.08 mmol). The solution was stirre
d at rt for 2 h. Water was added, and the aqueous layer was extracted with dichloromethane. The combi
ned organic layers were washed with brine, dried over Na2SO4, filtered and evaporated under reduced pr
essure. The crude product was purified by silica gel flash chromatography (ethyl acetate-n-hexane) to aff
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ord II-16 in 87% yield. 
1
H NMR (CDCl3, 400 MHz)  1.52-1.62 (4H, m), 1.63-1.70 (6H, m), 1.80-1.90 (2H, m), 1.95-2.01 (6H, m), 
2.05-2.11 (3H, m), 3.12 (2H, s), 3.15-3.25 (2H, m), 3.28-3.45 (4H, m), 3.58 (1H, s) , 3.75 (1H, t, J = 6.8 Hz), 4.08 
and 4.12 (1H, brs), 6.92-6.98 (2H, m) , 7.33-7.38 (1H, m). 
MS (ESI) m/z 458 [M+H]
+
. 
 
Diethyl 2,2'-(1-benzylpiperidine-4,4-diyl)diacetate (II-7). 
1-Benzylpiperidin-4-one (10 g, 53 mmol) and ethyl 2-cyanoacetate (11.3 ml, 106 mmol) were dissolved
 to a saturated ethanol solution of ammonia, and the solution was stirred at 0 C for 16 h. The solutio
n was filtered, and the residue was dissolved to 50% aqueous H2SO4 (45 ml). The solution was refluxe
d for 3 days. The solution was evaporated under reduced pressure, and the residue was azeotroped with
 ethanol. To the residue ethanol (50 ml) was added, and the mixture was refluxed for 20 h. A saturate
d aqueous solution of Na2CO3 was added, and the aqueous layer was extracted with dichloromethane. T
he combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated under r
educed pressure to afford II-7 in 52% yield. 
1
H NMR (CDCl3, 400 MHz)  1.24 (6H, t, J = 6.8 Hz), 1.68 (4H, t, J = 5.2 Hz), 2.45-2.49 (4H, m), 2.56 (4H, s), 
3.51 (2H, s), 4.10 (4H, q, J = 6.8 Hz), 7.23-7.30 (5H, m). 
MS (ESI) m/z 348 [M+H]
+
. 
 
2,2'-(1-benzylpiperidine-4,4-diyl)diethanol (II-8). 
To a suspension of LiAlH4 (2.1 g, 55 mmol) in diethyl ether (200 ml) cooled at -30 C was added a solution of 
diethyl 2,2'-(1-benzylpiperidine-4,4-diyl)diacetate (II-7) (12.2 g, 35 mmol) in diethyl ether (25 ml). The mixture 
was stirred at rt for 16 h. 1 M aqueous NaOH was added, and the mixture was filtered through a pad of Celite. The 
aqueous layer was extracted with diethyl ether. The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and evaporated under reduced pressure to afford II-8 in 76% yield. 
1
H NMR (CDCl3, 400 MHz)  1.52 (4H, t, J = 5.6 Hz), 1.68 (4H, t, J = 6.8 Hz), 2.40-2.45 (4H, m), 3.51 (2H, s), 
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3.73 (4H, t J = 6.8 Hz), 7.24-7.32 (5H, m). 
MS (ESI) m/z 264 [M+H]
+
. 
 
tert-Butyl 4,4-bis(2-hydroxyethyl)piperidine-1-carboxylate (II-9). 
 To a solution of 2,2'-(1-benzylpiperidine-4,4-diyl)diethanol (II-8) (415 mg, 1.58 mmol) and di-tert-butyl 
dicarbonate in methanol (12 ml) was added 10% Pd(OH)2 on carbon (45 mg). Under hydrogen atmosphere, the 
mixture was stirred at rt for 16 h and filtered through a pad of Celite. The solvent was removed under reduced 
pressure. The crude product was purified by silica gel flash chromatography (ethyl acetate-n-hexane) to afford 
II-9 in quantitative yield. 
1
H NMR (CDCl3, 400 MHz)  1.43-1.46 (13H, m), 1.71 (4H, t, J = 6.4 Hz), 3.40 (4H, t, J = 5.6 Hz), 3.76 (4H, t, J 
= 6.4 Hz). 
 
tert-Butyl 4,4-bis(2-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate (II-10). 
To a solution of tert-butyl 4,4-bis(2-hydroxyethyl)piperidine-1-carboxylate (II-9) (431 mg, 1.58 mmol) an
d methanesulfonyl chloride (0.27 ml, 3.47 mmol) in dichloromethane (7 ml) was added triethylamine (0.6
 ml, 4.34 mmol). The solution was stirred at -20 C for 2 h. 1 M aqueous HCl was added, and the aq
ueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, d
ried over Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by sili
ca gel flash chromatography (ethyl acetate-n-hexane) to afford II-10 in quantitative yield. 
1
H NMR (CDCl3, 400 MHz)  1.46-1.49 (13H, m), 1.90 (4H, t, J = 6.8 Hz), 3.04 (6H, s), 3.42 (4H, t, J = 6.0 Hz), 
4.32 (4H, t, J = 6.8 Hz). 
 
tert-Butyl 9-benzyl-3,9-diazaspiro[5.5]undecane-3-carboxylate (II-11). 
A mixture of tert-butyl 4,4-bis(2-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate (II-10) (300 mg, 0.70
 mmol) and benzylamine (0.38ml, 3.49mmol) was stirred at 80 C for 16 h. Water was added, and the 
aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine,
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 dried over Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by s
ilica gel flash chromatography (ethyl acetate-n-hexane) to afford II-11 in 75% yield. 
1
H NMR (CDCl3, 400 MHz)  1.38-1.43 (4H, m), 1.44 (9H, s), 1.49-1.52 (4H, m), 2.38-2.42 (4H, m), 3.30-3.38 
(4H, s), 3.50 (2H, s), 7.24-7.26 (1H, m), 7.28-7.31 (4H, m). 
MS (ESI) m/z 345 [M+H]
+
. 
 
(9-Benzyl-3,9-diazaspiro[5.5]undecan-3-yl)(2,6-difluorophenyl)methanone (II-13-B2). 
To a solution of tert-butyl 9-benzyl-3,9-diazaspiro[5.5]undecane-3-carboxylate (II-11) (181 mg, 0.53 mmol) in 
methanol (5 ml) was added HCl in methanol (20%, 5 ml). The solution was stirred at rt for 2 h. The solvent was 
removed under reduced pressure. To a solution of the resulting residue and 2,6-difluorobenzoyl chloride (66.1 μl, 
0.53 mmol) in dichloromethane (1 ml) was added triethylamine (0.11 ml, 0.79 mmol). The solution was stirred at 
rt for 2 h. Water was added, and the aqueous layer was extracted with dichloromethane. The combined organic 
layers were washed with brine, dried over Na2SO4, filtered and evaporated under reduced pressure. The crude 
product was purified by silica gel flash chromatography (ethyl acetate-n-hexane) to afford II-13-B2 91% yield. 
1
H NMR (CDCl3, 400 MHz)  1.45 (2H, t, J = 6.0 Hz), 1.51-1.61 (6H, m), 2.40 (4H, t, J = 5.6 Hz), 3.25 (2H, t, J 
= 5.6 Hz), 3.50 (2H, s), 3.76 (2H, t, J = 6.4 Hz), 6.91-6.94 (2H, m), 7.23-7.36 (6H, m). 
MS (ESI) m/z 385 [M+H]
+
. 
 
N-(Adamantan-1-yl)-9-(2,6-difluorobenzoyl)-3,9-diazaspiro[5.5]undecane-3-carboxamide (II-17). 
To a solution of (9-benzyl-3,9-diazaspiro[5.5]undecan-3-yl)(2,6-difluorophenyl)methanone (II-13-B2) (153m
g､0.39 mmol) in methanol (4 ml) was added 10% Pd(OH)2 on carbon (51 mg). Under hydrogen atmosp
here, the solution was stirred at rt for 18 h and filtered through a pad of Celite. The solvent was remov
ed under reduced pressure. To a solution of the resulting residue (25 mg) and adamantan-1-yl isocyanate
 (19 mg, 0.11 mmol) in dichloromethane was added (0.5 ml) DIPEA (23 μl, 0.13 mmol). The solution 
was stirred at rt for 30 min. Water was added, and the aqueous layer was extracted with dichloromethan
e. The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated und
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er reduced pressure. The crude product was purified by silica gel flash chromatography (ethyl acetate-n-h
exane) to afford II-17 (33 mg). 
1
H NMR (CDCl3, 400 MHz)  1.45-1.63 (8H, m), 1.65-1.69 (6H, m), 1.98-2.00 (6H, m), 2.05-2.12 (3H, m), 
3.26-3.33 (6H, m), 3.75-3.82 (2H, m), 4.21 (1H, s), 6.91-7.00 (2H, m), 7.30-7.38 (1H, m). 
MS (ESI) m/z 472 [M+H]
+
. 
 
Starting from corresponding isocyanates compounds in Table 2-4 were obtained following the procedure 
described for-N-(adamantan-1-yl)-8-(2,6-difluorobenzoyl)-2,8-diazaspiro[4.5]decane-2-carboxamide (II-15). 
 
Table 2-4. Data of compunds. 
Compound Name 
yield 
(%) 
1
H NMR (CDCl3, 400MHz) 
MS(ESI) 
[M+H]
+
 
II-18 
8-(2,6-difluorobenzoyl
)-N-(4-methoxyphenyl
)-2,8-diazaspiro[4.5]de
cane-2-carboxamide 
65 
1.55-1.66 (2H, m), 1.71-1.79 (2H, m), 1.89-1.99 
(2H, m), 3.28-3.45 (4H, m), 3.50-3.61 (2H, m), 
3.64-3.75 (1H, m), 3.78 (3H, s), 3.95-4.05 (1H, m), 
6.02 (1H, s), 6.84 (2H, d, J = 8.8 Hz), 6,92-6.98 
(2H, m), 7.26-7.39 (3H, m). 
430 
II-19 
N-(4-cyanophenyl)-8-(
2,6-difluorobenzoyl)-2
,8-diazaspiro[4.5]deca
ne-2-carboxamide 
16 
1.55-1.64 (2H, m), 1.72-1.74 (2H, m), 1.89-2.01 
(2H, m), 3.28-3.48 (4H, m), 3.52-3.55 (2H, m), 
3.65-3.75 (1H, m), 3.93-4.02 (1H, m), 6.52 (1H, s), 
6.91-6.98 (2H, m), 7.31-7.41 (1H, m), 7.53-7.55 
(4H, m). 
425 
II-20 
N-(4-chlorophenyl)-8-
(2,6-difluorobenzoyl)-
2,8-diazaspiro[4.5]dec
ane-2-carboxamide 
71 
1.57-1.65 (2H, m), 1.70-1.79 (2H, m), 1.90-1.99 
(2H, m), 3.26-3.45 (4H, m), 3.50-3.61 (2H, m), 
3.62-3.75 (1H, m), 3.92-4.01 (1H, m), 6.11 (1H, s), 
6,93-7.00 (2H, m), 7.21-7.39 (5H, m). 
434 
II-21 
8-(2,6-difluorobenzoyl
)-N-(4-(trifluoromethy
l)phenyl)-2,8-diazaspir
o[4.5]decane-2-carbox
amide 
56 
1.50-1.63 (2H, m), 1.70-1.77 (2H, m), 1.90-2.01 
(2H, m), 3.28-3.50 (4H, m), 3.53-3.65 (2H, m), 
3.62-3.78 (1H, m), 3.95-4.03 (1H, m), 6.29 (1H, s),  
6.92-7.00 (2H, m), 7.26-7.41 (1H, m) , 7.52-7.54 
(4H, m). 
468 
II-22 
8-(2,6-difluorobenzoyl
)-N-(4-(trifluorometho
66 
1.55-1.64 (2H, m), 1.71-1.76 (2H, m), 1.89-2.01 
(2H, m), 3.28-3.47 (4H, m), 3.51-3.62 (2H, m), 
484 
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xy)phenyl)-2,8-diazas
piro[4.5]decane-2-carb
oxamide 
3.65-3.76 (1H, m), 3.95-4.05 (1H, m), 6.20 (1H, s), 
6.92-6.99 (2H, m), 7.25 (2H, d, J = 8.0 Hz), 
7.31-7.41 (1H, m), 7.42 (2H, d, J = 8.0 Hz). 
II-24 
8-(2,6-difluorobenzoyl
)-N-(3-(trifluoromethy
l)phenyl)-2,8-diazaspir
o[4.5]decane-2-carbox
amide 
77 
1.59-1.66 (2H, m), 1.71-1.78 (2H, m), 1.91-1.99 
(2H, m), 3.29-3.66 (6H, m), 3.67-3.79 (1H, m), 
3.92-4.02 (1H, m), 6.24 (1H, s), 6,93-7.00 (2H, m), 
7.23-7.72 (5H, m). 
468 
II-27 
N-(3,4-dichlorophenyl
)-8-(2,6-difluorobenzo
yl)-2,8-diazaspiro[4.5]
decane-2-carboxamide 
70 
1.60-1.67 (2H, m), 1.71-1.79 (2H, m), 1.91-2.01 
(2H, m), 3.28-3.50 (4H, m), 3.51-3.68 (2H, m), 
3.68-3.79 (1H, m), 3.91-4.05 (1H, m), 6.76 (1H, s), 
6.91-7.00 (2H, m), 7.21-7.39 (3H, m), 8.26 (1H, d, 
J = 8.8 Hz). 
469 
II-29 
N-(2,4-dichlorophenyl
)-8-(2,6-difluorobenzo
yl)-2,8-diazaspiro[4.5]
decane-2-carboxamide 
71 
1.60-1.67 (2H, m), 1.71-1.79 (2H, m), 1.91-2.01 
(2H, m), 3.28-3.50 (4H, m), 3.51-3.68 (2H, m), 
3.68-3.79 (1H, m), 3.91-4.05 (1H, m), 6.76 (1H, s), 
6.91-7.00 (2H, m), 7.21-7.39 (3H, m), 8.26 (1H, d, 
J = 8.8 Hz). 
469 
 
N-(4-Chloro-3-(trifluoromethyl)phenyl)-8-(2,6-difluorobenzoyl)-2,8-diazaspiro[4.5]decane-2-carboxamide 
(II-26). 
To a solution of 4-nitrophenyl chloroformate (36 mg, 0.18 mmol) in dichloromethane (0.50 ml) were ad
ded 4-chloro-3-(trifluoromethyl)aniline (35 mg, 0.18 mmol) and DIPEA (31 μl, 0.18 mmol) in dichlorome
thane (1.0 ml). The solution was stirred at rt for 5 min. (2,6-difluorophenyl)(2,8-diazaspiro[4.5]decan-8-yl)
methanone (38 mg, 0.13 mmol) in dichloromethane (1.5 ml) and DIPEA (54 μl, 0.31 mmol) was added.
 The solution was stirred at rt for 2 h. A saturated aqueous solution of NaHCO3 was added, and the aq
ueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, d
ried over Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by sili
ca gel flash chromatography (ethyl acetate-n-hexane) to afford II-26 in 30% yield. 
1
H NMR (CDCl3, 400 MHz)  1.60-1.65 (2H, m), 1.71-1.79 (2H, m), 1.91-1.99 (2H, m), 3.29-3.50 (4H, m), 
3.51-3.65 (2H, m), 3.65-3.79 (1H, m), 3.92-4.05 (1H, m), 6.26 (1H, s), 6.92-7.01 (2H, m), 7.30-7.43 (2H, m), 
7.61-7.74 (2H, m). 
 32 
 
MS (ESI) m/z 502 [M+H]
+
. 
 
Starting from corresponding amines compounds in Table 2-5 were obtained following the procedure described 
for-N-(4-chloro-3-(trifluoromethyl)phenyl)-8-(2,6-difluorobenzoyl)-2,8-diazaspiro[4.5]decane-2-carboxamide 
(II-26). 
 
Table 2-5. Data of compunds. 
Compound Name 
yield 
(%) 
1
H NMR (CDCl3, 400MHz) 
MS(ESI) 
[M+H]
+
 
II-23 
8-(2,6-difluorobenzoyl
)-N-(4-(2,2,2-trifluoro
ethoxy)phenyl)-2,8-dia
zaspiro[4.5]decane-2-c
arboxamide 
71 
1.55-1.65 (2H, m), 1.70-1.78 (2H, m), 1.89-1.99 
(2H, m), 3.25-3.47 (4H, m), 3.50-3.61 (2H, m), 
3.61-3.75 (1H, m), 3.92-4.03 (1H, m), 4.31 (2H, 
dd, J = 8.1, 16.3 Hz), 6.06 (1H, s), 6.86-6.99 (4H, 
m), 7.29-7.38 (3H, m). 
498 
II-25 
8-(2,6-difluorobenzoyl
)-N-(3-(2,2,2-trifluoro
ethoxy)phenyl)-2,8-dia
zaspiro[4.5]decane-2-c
arboxamide 
61 
1.60-1.67 (2H, m), 1.71-1.79 (2H, m), 1.91-2.01 
(2H, m), 3.28-3.50 (4H, m), 3.51-3.68 (2H, m), 
3.68-3.79 (1H, m), 3.91-4.05 (1H, m), 6.76 (1H, 
s), 6.91-7.00 (2H, m), 7.21-7.39 (3H, m), 8.26 
(1H, d, J = 8.8 Hz). 
498 
II-28 
N-(4-chloro-3-methylp
henyl)-8-(2,6-difluoro
benzoyl)-2,8-diazaspir
o[4.5]decane-2-carbox
amide 
62 
1.58-1.65 (2H, m), 1.70-1.77 (2H, m), 1.90-1.99 
(2H, m), 2.34 (3H, s), 3.24-3.46 (4H, m), 
3.49-3.61 (2H, m), 3.62-3.75 (1H, m), 3.92-4.03 
(1H, m), 6.07 (1H, s), 6.89-7.01 (3H, m), 
7.11-7.39 (3H, m). 
448 
 
tert-Butyl 2-benzyl-2,8-diazaspiro[4.5]decane-8-carboxylate (II-52). 
To a solution of 2-benzyl-2,8-diazaspiro[4.5]decane (II-5) (5.0 g, 21 mmol) in water (20 ml) were adde
d di-tert-butyl dicarbonate (7.2 g, 33 mmol) and NaOH (2.64 g, 66 mmol). The solution was stirred at r
t for 3 h. The aqueous layer was extracted with dichloromethane. The combined organic layers were was
hed with brine, dried over Na2SO4, filtered and evaporated under reduced pressure to afford II-52 in 8
4% yield. 
 33 
 
1
H NMR (CDCl3, 400 MHz)  1.44 (9H, s), 1.47-1.52 (2H, m), 1.59-1.67 (4H, m), 2.37 (2H, s), 2.54-2.64 (2H, m), 
3.24-3.40 (4H, m), 3.58 (2H, s), 7.22-7.25 (1H, m), 7.29-7.33 (4H, m). 
 
tert-Butyl 2,8-diazaspiro[4.5]decane-8-carboxylate (II-53). 
Starting from tert-butyl 2-benzyl-2,8-diazaspiro[4.5]decane-8-carboxylate (II-52) the title compound was o
btained following the procedure described for (2,6-difluorophenyl)(2,8-diazaspiro[4.5]decan-8-yl)methanone 
(II-14B1) in 94% yield. 
1
H NMR (CDCl3, 400 MHz)  1.44 (9H, s), 1.50-1.70 (8H, m), 3.35-3.50 (6H, m). 
 
tert-Butyl 2-((4-(trifluoromethoxy)phenyl)carbamoyl)-2,8-diazaspiro[4.5]decane-8-carboxylate (II-54). 
Starting from tert-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate (II-53) and 4-(trifluoromethoxy)phenyl is
ocyanate the title compound was obtained following the procedure described for-N-(adamantan-1-yl)-8-(2,6
-difluorobenzoyl)-2,8-diazaspiro[4.5]decane-2-carboxamide (II-15) in 68% yield. 
1
H NMR (CDCl3, 400 MHz)  1.46 (9H, s), 1.52-1.58 (4H, m), 1.88 (2H, t, J = 6.9 Hz), 3.28-3.35 (4H, m), 
3.46-3.56 (4H, m), 6.16 (1H, brs), 7.14 (2H, d, J = 8.7 Hz), 7.43 (2H, d, J = 8.7 Hz). 
 
N-(4-(Trifluoromethoxy)phenyl)-2,8-diazaspiro[4.5]decane-2-carboxamide (II-55). 
To a solution of tert-butyl 2-((4-(trifluoromethoxy)phenyl)carbamoyl)-2,8-diazaspiro[4.5]decane-8-carboxylat
e (II-54) (1.0 g, 2.26 mmol) in dichloromethane (10 ml) was added TFA (1.22 ml, 15.8 mmol). The sol
ution was stirred at rt for 2 h. A saturated aqueous solution of NaHCO3 was added, and the aqueous lay
er was extracted with dichloromethane. The combined organic layers were washed with brine, dried over
 Na2SO4, filtered and evaporated under reduced pressure to afford II-55 in 75% yield. 
1
H NMR (CDCl3, 400 MHz)  1.54-1.58 (4H, m), 1.87 (2H, t, J = 7.3 Hz), 2.76-2.95 (4H, m), 3.34 (2H, s), 3.53 
(2H, t, J = 7.3 Hz), 6.18 (1H, brs). 7.14 (2H, d, J = 8.2 Hz), 7.43 (2H, d, J = 8.2 Hz). 
MS (ESI) m/z 344 [M+H]
+
. 
 
 34 
 
8-(2-Methylcyclopropanecarbonyl)-N-(4-(trifluoromethoxy)phenyl)-2,8-diazaspiro[4.5]decane-2-carboxami
de (II-46). 
To a solution of 2-methylcyclopropanecarboxylic acid (26 mg, 0.26 mmol) in DMF (1 ml) were added HATU 
(80 mg, 0.21 mmol), DIPEA (61 μl, 0.35 mmol) 
and-N-(4-(trifluoromethoxy)phenyl)-2,8-diazaspiro[4.5]decane-2-carboxamide (II-55) (60 mg, 0.18 mmol). The 
solution was stirred at rt for 16 h. Water was added, and the aqueous layer was extracted with ethyl acetate. The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated under reduced 
pressure. The crude product was purified by silica gel flash chromatography (ethyl acetate-n-hexane) to afford 
II-46 in quantitative yield. 
1
H NMR (CDCl3, 400 MHz)  0.55-0.62 (1H, m), 1.12 (3H, d, J = 5.9 Hz), 1.13-1.19 (1H, m), 1.26 (1H, t, J = 6.8 
Hz), 1.41-1.47 (1H, m), 1.52-1.68 (4H, m), 1.92 (2H, t, J = 6.8 Hz), 3.40 (2H, s), 3.56 (4H, t, J = 6.8 Hz), 
3.71-3.80 (2H, m), 6.19 (1H, s), 7.15 (2H, d, J = 8.6 Hz), 7.43 (2H, d, J = 8.6 Hz). 
MS (ESI) m/z 426 [M+H]
+
. 
 
Starting from corresponding aminoacids compounds in Table 2-6 were obtained following the procedure 
described for 8-(2-methylcyclopropanecarbonyl)-N-(4-(trifluoromethoxy)phenyl)-2,8-diazaspiro[4.5]decane-2-ca
rboxamide (II-46). 
 
Table 2-6. Data of compunds. 
Compound Name 
yield 
(%) 
1
H NMR (CDCl3, 400MHz) 
MS(ESI) 
[M+H]
+
 
II-30 
8-(2-fluorobenzoyl)-N-(4
-(trifluoromethoxy)phen
yl)-2,8-diazaspiro[4.5]de
cane-2-carboxamide 
87 
1.50-1.62 (2H, m), 1.68-1.78 (2H, m), 
1.88-2.00 (2H, m), 3.23-3.48 (4H, m), 
3.48-3.78 (3H, m), 3.90-4.02 (1H, br), 6.16 
(1H, s), 7.07-7.17 (3H, m), 7.22 (1H, t, J = 
3.6 Hz), 7.36-7.45 (4H, m). 
466 
II-31 
8-(2-fluoro-5-hydroxybe
nzoyl)-N-(4-(trifluorome
thoxy)phenyl)-2,8-diazas
68 
1.53-1.78 (4H, m), 1.88-2.00 (2H, m), 
3.32-3.50 (4H, m), 3.50-3.62 (2H, m), 
3.65-3.75 (1H, m), 3.81-3.92 (1H, m), 
482 
 35 
 
piro[4.5]decane-2-carbo
xamide 
6.69-6.74 (1H, m), 6.84 (1H, dt, J = 3.6, 8.6 
Hz), 6.97-7.04 (1H, m), 7.16 (2H, d, J = 8.6 
Hz), 7.50 (2H, d, J = 8.6 Hz). 
II-33 
8-(quinoline-5-carbonyl)
-N-(4-(trifluoromethoxy)
phenyl)-2,8-diazaspiro[4
.5]decane-2-carboxamid
e 
96 
1.43-1.57 (1H, m), 1.61-1.80 (3H, m), 
1.88-1.98 (2H, m), 3.12-3.48 (4H, m), 
3.49-3.77 (3H, m), 3.92-4.03 (1H, m), 6.16 
(1H, s), 7.14 (2H, d, J = 8.6 Hz), 7.26-7.35 
(3H, m), 7.39-7.45 (3H, m). 
499 
II-34 
8-(1H-benzo[d]imidazol
e-4-carbonyl)-N-(4-(trifl
uoromethoxy)phenyl)-2,
8-diazaspiro[4.5]decane-
2-carboxamide 
75 
1.52-1.80 (4H, br), 1.95 (2H, t, J = 6.3 Hz), 
3.35 (2H, s), 3.38-3.80 (6H, m), 7.16 (2H, d, J 
= 9.1 Hz), 7.36 (2H, dd, J = 1.4, 8.6 Hz), 7.50 
(2H, d, J = 9.1 Hz), 7.66-7.76 (2H, br), 8.28 
(1H, s). 
488 
II-35 
8-(5-methylpyrazine-2-c
arbonyl)-N-(4-(trifluoro
methoxy)phenyl)-2,8-dia
zaspiro[4.5]decane-2-car
boxamide 
94 
1.58-1.70 (2H, t, J = 5.9 Hz), 1.71-1.78 (2H, 
m), 1.95 (2H, td, J = 2.7, 7.0 Hz), 2.63 (3H, 
s), 3.38-3.73 (7H, m) 3.91-4.01 (1H, m), 6.18 
(1H, s), 7.15 (2H, d, J = 8.6 Hz), 7.43 (2H, d, 
J = 8.6 Hz), 8.41 (1H, brs), 8.83 (1H, brs). 
464 
II-36 
8-(5-methylisoxazole-3-
carbonyl)-N-(4-(trifluoro
methoxy)phenyl)-2,8-dia
zaspiro[4.5]decane-2-car
boxamide 
30 
1.63-1.72 (4H, m), 1.95 (2H, t, J = 7.7 Hz), 
2.48 (3H, s), 3.38-3.45 (2H, m), 3.53-3.73 (4H, 
m), 3.89-4.01 (2H, m), 6.16 (1H, s), 6.28 (1H, 
s), 7.15 (2H, d, J = 8.6 Hz), 7.44 (2H, d, J = 
8.6 Hz). 
452 
II-37 
8-(5-cyclopropylisoxazol
e-4-carbonyl)-N-(4-(trifl
uoromethoxy)phenyl)-2,
8-diazaspiro[4.5]decane-
2-carboxamide 
19 
1.12-1.20 (2H, m), 1.21-1.27 (2H, m), 
1.60-1.75 (4H, br), 1.96 (2H, t, J = 7.3 Hz), 
2.24-2.32 (1H, m), 3.44 (2H, s), 3.47-4.00 (6H, 
br), 6.16 (1H, s), 7.15 (2H, d, J = 9.1 Hz), 7.42 
(2H, d, J = 9.1 Hz), 8.19 (1H, s). 
479 
II-38 
8-(2-methylfuran-3-carb
onyl)-N-(4-(trifluoromet
hoxy)phenyl)-2,8-diazas
piro[4.5]decane-2-carbo
xamide 
71 
1.55-1.70 (4H, br), 1.94 (2H, t, J = 7.3 Hz), 
2.39 (3H, s), 3.42 (2H, s), 3.44-3.95 (6H, m), 
6.16 (1H, s), 6.34 (1H, d, J = 1.8 Hz), 7.15 
(2H, d, J = 8.6 Hz), 7.27 (1H, brs), 7.43 (2H, 
d, J = 8.6 Hz). 
452 
II-40 
8-(tetrahydrofuran-3-car
bonyl)-N-(4-(trifluorome
thoxy)phenyl)-2,8-diazas
piro[4.5]decane-2-carbo
xamide 
69 
1.52-1.68 (4H, m), 1.91 (2H, t, J = 7.3 Hz), 
2.02-2.14 (1H, m), 2.12-2.30 (1H, m), 
3.20-3.30 (1H, m), 3.40 (2H, s), 3.41-3.50 (1H, 
m), 3.52-3.62 (3H, m), 3.76-3.92 (5H, m), 4.01 
(1H, t, J = 8.2 Hz), 6.26 (1H, s), 7.14 (2H, d, 
442 
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J = 8.6 Hz), 7.43 (2H, d, J = 8.6 Hz). 
II-41 
8-(tetrahydro-2H-pyran-
4-carbonyl)-N-(4-(trifluo
romethoxy)phenyl)-2,8-
diazaspiro[4.5]decane-2-
carboxamide 
50 
1.51-1.68 (6H, m), 1.87-1.98 (4H, m), 2.74 
(1H, tt, J = 3.6, 11 Hz), 3.36-3.51 (6H, m), 
3.51-3.63 (3H, m), 3.75-3.87 (1H, br), 4.03 
(2H, dq, J = 2.3, 11 Hz), 6.16 (1H, s), 7.15 
(2H, d, J = 8.6 Hz), 7.43 (2H, d, J = 8.6 Hz). 
456 
II-43 
8-(4-hydroxycyclohexan
ecarbonyl)-N-(4-(trifluor
omethoxy)phenyl)-2,8-di
azaspiro[4.5]decane-2-ca
rboxamide 
29 
1.47-1.80 (8H, m), 1.82-2.02 (6H, m), 2.52 
(1H, tt, J = 3.2, 11 Hz), 3.32-3.48 (4H, m), 
3.55 (2H, t, J = 6.8 Hz), 3.60-3.69 (1H, m), 
3.71-3.84 (1H, m), 4.02 (1H, brs), 6.29 (1H, s), 
7.14 (2H, d, J = 8.6 Hz), 7.43 (2H, d, J = 8.6 
Hz). 
470 
II-44 
N-(4-(trifluoromethoxy)
phenyl)-8-(1-(trifluorom
ethyl)cyclopropanecarbo
nyl)-2,8-diazaspiro[4.5]d
ecane-2-carboxamide 
37 
1.16 (2H, t, J = 5.9 Hz), 1.34 (2H, t, J = 5.9 
Hz), 1.55-1.70 (4H, m), 1.93 (2H, t, J = 7.3 
Hz), 3.41 (2H, s), 3.46-3.62 (4H, m), 3.81 (2H, 
dt, J = 5.0, 13 Hz), 6.17 (1H, s), 7.15 (2H, d, 
J = 8.6 Hz), 7.43 (2H, d, J = 8.6 Hz). 
480 
II-45 
8-(2,2-difluorocycloprop
anecarbonyl)-N-(4-(triflu
oromethoxy)phenyl)-2,8
-diazaspiro[4.5]decane-2
-carboxamide 
48 
1.16 (2H, t, J = 5.9 Hz), 1.34 (2H, t, J = 5.9 
Hz), 1.55-1.70 (4H, m), 1.93 (2H, t, J = 7.3 
Hz), 3.41 (2H, s), 3.46-3.62 (4H, m), 3.81 (2H, 
dt, J = 5.0, 13 Hz), 6.17 (1H, s), 7.15 (2H, d, 
J = 8.6 Hz), 7.43 (2H, d, J = 8.6 Hz). 
448 
II-47 
8-(2-cyclopropylacetyl)-
N-(4-(trifluoromethoxy)
phenyl)-2,8-diazaspiro[4
.5]decane-2-carboxamid
e 
87 
0.15-0.22 (2H, m), 0.53-0.61 (2H, m), 
0.94-1.10 (1H, M), 1.50-1.73 (4H, m), 1.90 
(2H, t, J = 7.1 Hz), 2.29 (2H, d, J = 6.8 Hz), 
3.32-3.63 (7H, m), 3.70-3.84 (1H, m), 6.19 
(1H, s), 7.14 (2H, d, J = 8.0 Hz), 7.43 (2H, d, J 
= 8.0 Hz). 
426 
II-49 
8-(2-ethylbutanoyl)-N-(4
-(trifluoromethoxy)phen
yl)-2,8-diazaspiro[4.5]de
cane-2-carboxamide 
9 
0.82-0.91 (6H, m), 1.41-1.53 (1H, m), 
1.54-1.71 (7H, m), 1.92 (2H, t, J = 6.8 Hz), 
2.49-2.58 (1H, m), 3.40 (2H, s), 3.43-3.71 (5H, 
m), 3.80-3.91 (1H, br), 6.20 (1H, s), 7.14 (2H, 
d, J = 8.6 Hz), 7.43 (2H, d, J = 8.6 Hz). 
442 
II-51 
8-(3-(3-hydroxyphenyl)p
ropanoyl)-N-(4-(trifluoro
methoxy)phenyl)-2,8-dia
zaspiro[4.5]decane-2-car
boxamide 
71 
1.34-1.42 (2H, br), 1.50-1.60 (2H, br), 
1.81-1.90 (2H, m), 2.62 (2H, td, J = 1.7, 7.8 
Hz), 2.93 (2H, t, J = 7.8 Hz), 3.22-3.56 (7H, 
m), 3.71-3.80 (1H, m), 5.59 (1H, s), 6.19 (1H, 
s), 6.66-6.79 (3H, m), 7.12-7.18 (3H, m), 7.43 
492 
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(2H, d, J = 9.0 Hz). 
 
Starting from corresponding acyl halides and-N-(4-(trifluoromethoxy)phenyl)-2,8-diazaspiro[4.5]decane-2-ca
rboxamide (II-55) compounds in Table 2-7 were obtained following the procedure described for (2-benzyl
-2,8-diazaspiro[4.5]decan-8-yl)(2,6-difluorophenyl)methanone (II-13B1). 
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Table 2-7. Data of compunds. 
Compound Name 
yield 
(%) 
1
H NMR (CDCl3, 400MHz) 
MS(ESI) 
[M+H]
+
 
II-32 
8-(2-chlorobenzoyl)-N-(4-(
trifluoromethoxy)phenyl)-
2,8-diazaspiro[4.5]decane-
2-carboxamide 
90 
1.43-1.57 (1H, m), 1.61-1.80 (3H, m), 
1.88-1.98 (2H, m), 3.12-3.48 (4H, m), 
3.49-3.77 (3H, m), 3.92-4.03 (1H, m), 6.16 
(1H, s), 7.14 (2H, d, J = 8.6 Hz), 7.26-7.35 
(3H, m), 7.39-7.45 (3H, m). 
482 
II-39 
8-(furan-2-carbonyl)-N-(4-
(trifluoromethoxy)phenyl)-
2,8-diazaspiro[4.5]decane-
2-carboxamide 
94 
1.64-1.72 (4H, m), 1.95 (2H, t, J = 7.3 Hz), 
3.43 (2H, s), 3.57 (2H, t, J = 7.3 Hz), 
3.59-3.71 (2H, br), 3.87-3.97 (2H, m), 6.17 
(1H, s), 6.49 (1H, dd, J = 1.8, 3.6 Hz), 7.00 
(1H, d, J = 3.2 Hz), 7.15 (2H, d, J = 8.2 
Hz), 7.44 (2H, d, J = 8.2 Hz), 7.48 (1H, 
brs). 
438 
II-42 
8-(cyclohexanecarbonyl)-
N-(4-(trifluoromethoxy)ph
enyl)-2,8-diazaspiro[4.5]d
ecane-2-carboxamide 
41 
1.20-1.30 (4H, m), 1.45-1.72 (8H, m), 
1.77-1.84 (2H, m), 1.91 (2H, t, J = 7.3 Hz), 
2.47 (1H, tt, J = 3.2, 11.8 Hz), 3.35-3.50 
(4H, m), 3.51-3.62 (3H, m), 3.71-3.84 (1H, 
br), 6.15 (1H, s), 7.14 (2H, d, J = 8.6 Hz), 
7.43 (2H, d, J = 8.6 Hz). 
454 
II-48 
8-pivaloyl-N-(4-(trifluoro
methoxy)phenyl)-2,8-diaz
aspiro[4.5]decane-2-carbo
xamide 
28 
1.29 (9H, s), 1.57-1.63 (4H, m), 1.91 (2H, t, 
J = 7.3 Hz), 3.39 (2H, s), 3.44-3.60 (4H, 
m), 3.72-3.82 (2H, br), 6.15 (1H, s), 7.14 
(2H, d, J = 8.6 Hz), 7.43 (2H, d, J = 8.6 
Hz). 
428 
II-50 
8-pentanoyl-N-(4-(trifluor
omethoxy)phenyl)-2,8-dia
zaspiro[4.5]decane-2-carb
oxamide 
65 
0.93 (3H, t, J = 7.7 Hz), 1.32-1.42 (2H, m), 
1.52-1.65 (6H, m), 1.91 (2H, t, J = 7.3 Hz), 
2.34 (2H, t, J = 7.7 Hz), 3.33-3.62 (7H, m), 
3.73-3.84 (1H, m), 6.17 (1H, s), 7.14 (2H, d, 
J = 8.2 Hz), 7.43 (2H, d, J = 8.2 Hz). 
428 
 
Measurement of in vitro sEH inhibitory activity. 
The sEH inhibition assays were performed as described by Jones, P. D.; Wolf, N. M.; Morisseau, C.; Whetstone, 
P.; Hock, B.; Hammock, B. D.(Anal. Biochem. 2005, 343, 66.). A solution of recombinant sEH from human or 
 39 
 
mouse (the enzymes were purchased from Cayman Chemical Company) or rat (the enzyme was expressed in Sf9 
insect cells using baculovirus) in buffer (BisTris–HCl, 25 mM, pH 7.0, containing 0.1 mg/ml BSA) was incubated 
with a inhibitor at room temperature for 30 min. To the resultant solution, 
cyano(6-methoxy-naphthalen-2-yl)methyl trans-[(3-phenyloxiran-2-yl)methyl] carbonate (purchased from 
Cayman Chemical Company) was added, and the mixture was incubated at room temperture for 20-45 min. 
ZnSO4 was added, and the resultant solution of fluorescence intensity (excitation filter 330 nm, emission filter 465 
nm) was measured. The reduction rate of enzyme activity by inhibitors were calculated using the fluorescence 
intensity, and IC50 values were determined. In these assays IC50 values of a representative sEH inhibitor 
12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA) were 3 nM (human), 10 nM (murine), 10 nM (rat). 
 
Protocol of Docking Studies 
In order to get accurate results, all the docking experiments were performed with the default parameters.  
Protein was prepared by fred_receptor 2.2.5 software (Openeye Scientific Software, Santa Fe, NM) using 
Xray co-crystal structure(PDB code 1VJ5). Each compound was converted into the set of low-energy 3D 
multi-conformers by Omega 2.3.2 (Openeye Scientific Software Santa Fe, NM) in order to perform 
docking studies with FRED 2.2.4 software (Openeye Scientific Software, Santa Fe, NM) which uses 
multi-conformer docking algorithm, and then do rigid docking for each conformer. Up to 400 conformers 
were generated for each compound. 
Docking studies of sEH protein with the compounds conformers were performed by using FRED with a 
Gaussian type fitting scoring function Chemgauss3 to obtain the most reliable docking pose ac coording to 
the core scoring fuction. 
Chemgauss3 uses the potentials between the chemically matched positions around the docked ligand. 
These chemical positions are complementary to the surrounding specific groups in the protein. The 
interactions which can be scored by Chemgauss3 functions are: steric, acceptor, donors, coordinating 
groups, metals, lone pairs, polar hydrogens and chelator coordinating groups*. 
* Nature Reviews Drug Discovery 3, 935-949 
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Chapter 3 
Discovery of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted 
urea derivatives as highly potent soluble epoxide hydrolase inhibitors 
and orally active drug candidates for treatment of chronic kidney 
diseases 
 
Abstract: The identification of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted ureas as highly potent 
soluble epoxide hydrolase (sEH) inhibitors and orally active agents for treating chronic kidney diseases is 
described. III-22 exhibited excellent inhibitory activity against sEH and excellent bioavailability. When 
administered orally at 30 mg/kg, III-22 lowered serum creatinine in a rat model of anti-glomerular basement 
membrane (GBM) glomerulonephritis but 2,8-diazaspiro[4.5]decane-based trisubstituted ureas did not. These 
results suggest that III-22 is an orally active drug candidate for treating chronic kidney diseases. 
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Introduction 
 
As described in Chapter 2, I found that 2,8-diazaspiro[4.5]decane-based trisubstituted ureas are highly potent 
sEH inhibitors and orally active drug candidates for treating hypertension (Figure 3-1, II-22). I expected that these 
derivatives would show renal protective effects derived from the beneficial effects of sEH inhibitors described in 
Chapter 1. Contrary to my expectation, oral administration of these derivatives failed to reduce serum creatinine in 
a rat model of anti-GBM glomerulonephritis
1
. I found that the solubility and microsomal stability of 
2,8-diazaspiro[4.5]decane-based trisubstituted ureas can be conveniently modified by changing the substituent on 
the amide group. On the basis of these findings, I hypothesized that spirocyclic diamine-based trisubstituted ureas 
could be developed as sEH inhibitors and I aimed to find other such ureas that inhibited sEH as strongly as 
2,8-diazaspiro[4.5]decane-based trisubstituted ureas did and that had different pharmacokinetic profiles. 
 
Design 
 
As shown in Figure 3-1, I designed 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivative III-1. 
Because of its introduced oxygen atom, III-1 had lower cLogP than II-22 and thus had higher aqueous solubility. 
A docking study of III-1 with human sEH (Figure 3-2) suggested that the two carbonyl oxygen atoms of III-1 
bind to the catalytic pocket in the same manner as II-22. Working under this hypothesis, I began to explore 
1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives. In light of the docking study results 
(Figure 3-2), I also designed III-18, which has a carbon atom in place of the oxygen atom in the 
1-oxa-4,9-diazaspiro[5.5]undecane scaffold of III-1 (Figure 3-1); my expectation was that it would have sEH 
inhibitory activity as high as that of II-22. 
 
Figure 3-1. Structures of II-22, III-1 and III-18. 
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Figure 3-2. Docking studies of human sEH (PDB code: 1VJ5) with II-22 (left) and III-1 (right). 
 
Chemistry 
 
 The general procedure for the synthesis of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea 
derivatives III-1, III-22 to III-43, and III-11 is shown in Scheme 3-1. Starting material III-6 was synthesized by 
a reported method.
2
 III-2 was treated with trimethysilyl cyanide and Et3N, then the reaction mixture was added 
dropwise to a solution of LiAlH4. The obtained product, III-3, was treated with 2-chloroacetyl chloride affording 
III-4. Intramolecular cyclization of III-4 gave III-5. This step was detailed in Chapter 4. Reduction of the amide 
group in III-5 provided III-6. Treatment of III-6 with isocyanate afforded III-7. Removal of the benzyl protecting 
group by Pd(OH)2-catalyzed hydrogenation provided III-8. Then, condensation with carboxylic acid or acyl 
chloride produced III-1 and III-22 through III-43. Treatment of III-6 with benzoyl chloride afforded III-9. 
Removal of the benzyl protecting group by Pd(OH)2-catalyzed hydrogenation provided III-10. Then, treatment 
with isocyanate gave III-11. The synthesis of 2,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives 
III-18 and III-21 is shown in Scheme 3-2. Oxidation of alcohol III-12 with Dess-Martin periodinane afforded 
III-13. Michael addition to acrylonitrile provided III-14. Then, hydrogenation of the nitrile group was 
accompanied by cyclization via reductive amination to give 2,9-diazaspiro[5.5]undecane III-15. Treatment of 
III-15 with isocyanate, removal of the Boc protecting group by TFA, and then treatment with benzoyl chloride led 
to III-18. Treatment of III-15 with benzoyl chloride, removal of the Boc protectiong group by TFA, and then 
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treatment with isocyanate afforded III-21. 
 
 
Scheme 3-1. Synthesis of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives. 
 
 
Scheme 3-2. Synthesis of 2,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives. 
 
Results and discussion 
 
The diazaspiro-based urea derivatives listed in Table 3-1 to 3-4 had 1 or 2 hydrogen bond donors, 6-9 hydrogen 
bond acceptors, molecular mass of 447-519 Da, and an octanol-water partition coefficient log P of 0.90-3.89. 
III-28, III-37, III-41, and III-42 had molecular mass greater than 500. Other derivatives satisfied Lipinski’s rule. 
I performed structure–activity relationship (SAR) and structure–property relationship (SPR) studies on the 
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diazaspiro scaffolds (Table 3-1). 4-(Trifluoromethoxy)phenyl and 2,6-difluorobenzoyl groups were selected as the 
left- and right-hand substituents, respectively. As I expected, III-1 had moderate inhibitory activity against human 
sEH and better solubility than II-22. However, the microsomal stability of III-1 was lower than that of II-22. 
Lower sEH inhibitory activity was found in III-11, whose diazaspiro scaffold was constructed with the left- and 
right-hand substituents swapped. In III-18, which had a carbon atom in place of the oxygen atom in the 
1-oxa-4,9-diazaspiro[5.5]undecane scaffold of III-1, sEH inhibitory activity was improved but microsomal 
stability and solubility became problematically low. Replacing the oxygen atom of III-11 with a carbon atom also 
led to lower solubility (III-21). Considering that III-1 showed higher solubility, I next focused on derivatives with 
a 1-oxa-4,9-diazaspiro[5.5]undecane scaffold. 
Table 3-1. SAR and SPR of diazaspiro scaffolds. 
Structure Compound 
sEH IC50(nM) Solubility (g/mL) Human liver 
microsomal 
stability
a
 
cLogP 
Human Rat JP1
b
 JP2
c
 
 
II-22 0.4 4.5 24 21 0
 
3.33 
 
III-1 0.7 18.5 44 39 0.086 2.84 
 
 
III-11 5.4 N.D.d 52 46 N.D. 2.86 
 
 
III-18 0.125 3.3 9 9 0.602 3.89 
 
 
III-21 2.96 N.D. 0 0 N.D. 3.89 
a
 Units: mL/min/mg protein. 
b
 Simulated gastric fluid compliant with the Japanese Pharmacopoeia. 
c
 Simulated intestinal fluid compliant with the Japanese Pharmacopoeia. 
d
 N.D.: Not determined. 
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The SAR and SPR results for derivatives of III-1 with benzamide moieties are shown in Table 3-2. The 
removal of the fluorine atom from III-1 improved inhibitory activity against rat sEH, and also improved solubility 
and microsomal stability (III-22). Replacing the trifluoromethoxy group of III-1 with a trifluoromethyl group 
(III-23) made little difference in activity or other properties. The effect of substituent position on the benzamide 
ring was investigated (III-24 to III-27). Removing the substituent reduced human sEH inhibitory activity (III-24). 
Installing a chloro substituent at the ortho (III-25), meta (III-26), and para (III-27) positions gave the same 
human sEH inhibitory activity as III-23, and only III-25 showed improved inhibitory activity against rat sEH. 
III-25 and III-27 exhibited sufficient microsomal stability. These results suggest that ortho substitution on the 
aromatic benzamide ring is particularly favorable for rat sEH inhibitory activity but meta or para substitution is 
not. In general, lower lipophilicity corresponds to better solubility and microsomal stability.
3
 Aiming to achieve 
sufficient sEH inhibitory activity, solubility, and microsomal stability concurrently, I examined an 
ortho-substituted derivative with reduced lipophilicity (III-28); it had higher sEH inhibitory activity, solubility, 
and microsomal stability. Further investigation revealed that only a cyano group was tolerated at the para position 
on the benzamide ring: III-29 exhibited good sEH inhibitory activity, solubility, and microsomal stability. 
 
Table 3-2. SAR and SPR of 1-oxa-4,9-diazaspiro[5.5]undecane-based urea derivatives: substituents in benzene 
rings. 
 
R R' Compound 
sEH IC50(nM) Solubility (g/mL) Human liver 
microsomal 
stability 
cLogP 
Human Rat JP1b JP2c 
OCF3 
 
 
III-1 0.7 18.5 44 39 0.086 2.84 
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Table 3-2. SAR and SPR of 1-oxa-4,9-diazaspiro[5.5]undecane-based urea derivatives: substituents in benzene 
rings. 
R R' Compound 
sEH IC50(nM) Solubility (g/mL) Human liver 
microsomal 
stability 
cLogP 
Human Rat JP1b JP2c 
OCF3 
 
 
III-22 1.1 9.3 71 62 0.03 2.67 
CF3 
 
 
III-23 1.3 19.1 43 38 0.093 3.04 
CF3 
 
 
III-24 3.2 N.D.d 62 63 N.D. 2.66 
CF3 
 
 
III-25 1.4 13 10 12 0.048 3.44 
CF3 
 
 
III-26 1.2 36.9 26 21 0.1 3.44 
CF3 
 
 
III-27 1 24.9 29 23 0.021 3.44 
CF3 
 
 
III-28 0.8 6.8 92 93 0.039 2.14 
CF3 
 
 
III-29 1.9 15 85 82 0.003 2.26 
a
 Units: mL/min/mg protein. 
b
 Simulated gastric fluid compliant with the Japanese Pharmacopoeia. 
c
 Simulated intestinal fluid compliant with the Japanese Pharmacopoeia. 
d
 N.D.: Not determined. 
 
Derivatives with a heteroaromatic ring as the amide substituent were explored in order to evaluate the 
effectiveness of reduced lipophilicity for improving solubility and microsomal stability. As expected, almost all 
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compounds in Table 3-3 exhibited improved solubility and microsomal stability. However, I observed decreased 
human sEH inhibitory activity in III-30 which contained an unsubstituted five-membered ring. The derivatives 
with five-membered rings bearing a methyl or cyclopropyl substituent (III-31 to III-33) exhibited increased 
human sEH inhibitory activity. Remarkably, pyrazole derivative III-33, which contained an NH moiety, was 
tolerated in humans and exhibited sEH inhibitory activity, but was not tolerated in rats. III-34 with an 
unsubstituted pyridine ring showed lower activity, and III-35 with a chloro substituent on the pyridine ring 
effectively inhibited sEH in humans and rats. A pyrazine ring was also an applicable substituent (III-36). 
Although III-37 exhibited moderate human sEH inhibitory activity, its rat sEH inhibitory activity was greatly 
reduced. 
 
Table 3-3. SARs and SPRs of 1-oxa-4,9-diazaspiro[5.5]undecane-based urea derivatives: heteroaromatics. 
 
R R' Compound 
sEH IC50(nM) Solubility (g/mL) Human liver 
microsomal 
stability 
cLogP 
Human Rat JP1b JP2c 
CF3 
 
 
III-30 5.4 N.D. 75 75 N.D.d 1.83 
OCF3 
 
 
III-31 1.4 25.7 84 83 0.047 1.22 
OCF3 
 
 
III-32 0.6 22.2 86 89 0.087 1.67 
OCF3 
 
 
III-33 1.1 96.9 93 92 0.035 1.91 
CF3 
 
 
III-34 4.2 N.D. 85 83 N.D. 1.56 
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Table 3-3. SARs and SPRs of 1-oxa-4,9-diazaspiro[5.5]undecane-based urea derivatives: heteroaromatics. 
R R' Compound 
sEH IC50(nM) Solubility (g/mL) Human liver 
microsomal 
stability 
cLogP 
Human Rat JP1b JP2c 
OCF3 
 
 
III-35 0.6 11.6 90 89 0.062 2.10 
OCF3 
 
 
III-36 0.9 8.8 91 92 0.012 0.90 
OCF3 
 
 
III-37 1.8 >20 96 93 0.029 1.49 
a
 Units: mL/min/mg protein. 
b
 Simulated gastric fluid compliant with the Japanese Pharmacopoeia. 
c
 Simulated intestinal fluid compliant with the Japanese Pharmacopoeia. 
d
 N.D.: Not determined. 
 
Table 3-4 shows the results for derivatives with an aliphatic amide. III-38 with a pivalamide moiety had high 
inhibitory activity against human and rat sEH, and III-39 also showed increased human sEH inhibitory activity, 
but its rat sEH inhibitory activity was 0.4-fold that of III-38. III-40 exhibited potent sEH inhibitory activity but 
was labile to CYP-mediated metabolism. The derivatives with bulky substituents (III-41 to III-43) had moderate 
human sEH inhibitory activity, but showed decreased rat sEH inhibitory activity. 
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Table 3-4. SARs and SPRs of 1-oxa-4,9-diazaspiro[5.5]undecane-based urea derivatives: aliphatic amides. 
 
R R' Compound 
sEH IC50(nM) Solubility (g/mL) Human liver 
microsomal 
stability 
cLogP 
Human Rat JP1b JP2c 
CF3 
 
 
III-38 2.9 12 76 73 0.098 2.07 
CF3 
 
 
III-39 2.1 31.4 79 79 0.074 1.81 
OCF3 
 
 
III-40 0.6 14.5 69 63 0.357 2.67 
OCF3 
 
 
III-41 0.4 28 37 33 0.228 3.25 
OCF3 
 
 
III-42 0.5 71.6 66 59 0.461 2.82 
OCF3 
 
 
III-43 0.7 >20 92 90 0.132 1.41 
a
 Units: mL/min/mg protein. 
b
 Simulated gastric fluid compliant with the Japanese Pharmacopoeia. 
c
 Simulated intestinal fluid compliant with the Japanese Pharmacopoeia. 
d
 N.D.: Not determined. 
 
Considering sEH inhibitory activity, solubility and stability to CYP-mediated metabolism, I selected 
compounds III-22, III-28, and III-36 and evaluated their pharmacokinetic profiles (Table 3-5). III-22 had good 
bioavailability, whereas III-36 had modest bioavailability, which was attributed to low membrane permeability 
resulting from low lipophilicity (cLogP: 0.90).
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Table 3-5. Pharmacokinetic profiles of III-22, III-28, and III-36 in rat. a 
Compound 
i.v. (0.2 mg/kg) p.o. (1 mg/kg) 
C5min 
(ng/mL) 
AUC0-∞ 
(ng·hr/mL) 
t1/2 
(hr) 
CLtot 
(mL/hr/kg) 
Vdss 
(mL/kg) 
Cmax 
(ng/mL) 
AUC0-∞ 
(ng·hr/mL) 
tmax 
(hr) 
F 
(%) 
III-22 71 173 2.63 1157 3562 20.4 306 1 35.4 
III-28 77.7 90.2 1.17 2216 3315 9.58 123 2 24.1 
III-36 134 111 1.53 1808 1825 8.64 61.3 1 11.1 
a
 i.v.: Intravenous. p.o.: Oral administration. C: Concentration. AUC: Area under the blood concentration time 
curve. t1/2: Half-life. CLtot: Total body clearance. Vdss: Volume of distribution. F: Oral bioavailability. 
 
Next the effect of III-22 on serum creatinine levels in a rat model of anti-GBM glomerulonephritis was 
investigated 
1
 (Figure 3-4). Serum creatinine levels were significantly higher than in normal rat and increased in a 
time-dependent manner. Oral administration of III-22 at 30 mg/kg significantly reduced serum creatinine in the 
rat model. The result indicates that III-22 prevented the progression of glomerulonephritis. I do not yet know why 
2,8-diazaspiro[4.5]decane-based trisubstituted ureas failed to reduce serum creatinine levels in the rat model, but I 
speculate that these derivatives did not sufficiently penetrate into renal tissue. 
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Figure 3-4 Effect of III-22 on serum creatinine in a rat model of anti-GBM glomerulonephritis. III-22 (30 
mg/kg) was orally administered once daily for 3 weeks starting at 2 weeks after injection of anti-GBM antibody. 
Serum 
creatinine 
(mg/dL) 
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Summary 
 
In conclusion, I identified 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted ureas as highly potent sEH 
inhibitors and orally active agents for treating chronic kidney diseases. III-22 exhibited excellent inhibitory 
activity against sEH and excellent bioavailability, as well as a renal protective effect in a rat model of anti-GBM 
glomerulonephritis. These results suggest that III-22 is an orally active drug candidate for treating chronic kidney 
diseases. 
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Experimental Section 
General Information 
All reagents and solvents were of commercial quality and were used without further purification unless 
otherwise noted. 
1
H NMR spectra were recorded on JNM-AL400 at 400 MHz and are referenced to an internal 
standard of tetramethylsilane (TMS, 0). Chemical shifts are given in ppm. Coupling constants (J) are given in 
Hz. Multiplicities are abbreviated as singlet (s), doublet (d), triplet (t), quartet (q), doublet‐doublet (dd), 
multiplet (m), and broad (br). Mass spectra were recorded with electron-spray ionization (ESI) on a Waters 
ZQ-2000.Thin layer chromatography was performed using Merck Kieselgel 60 F254 plates (0.25 mm). Compounds 
were visualized by UV-light at 254 nm and color reagents. Flash chromatography was performed using Yamazen
 
HI-FLASH COLUMNS (Particle Size：40 m). Solvents were removed by rotary evaporation. 
 
4-(Aminomethyl)-1-benzylpiperidin-4-ol (III-3). 
Under argon atmosphere, to a mixture of 1-benzylpiperidin-4-one (III-2) (20 g, 106 mmol) and triethylamine 
(3.7 ml, 26.4 mmol) was added trimethylsilyl cyanide (15.6 g, 116 mmol). The solution was stirred at rt for 10 min. 
To a suspension of LiAlH4 (2.1 g, 55 mmol) in THF (100 ml) cooled at 0 C the reaction mixture was added. The 
solution was refluxed for 3 h. To the solution cooled at 0 C water (5.2 ml) was added 1M aqueous NaOH (5.2 ml) 
and water (10.4 ml). The solution was stirred at 0 C for 10 min. The mixture was filtered through a pad of Celite. 
The solvent was evaporated under reduced pressure to afford III-3 in 87% yield. 
1
H NMR (CDCl3, 400 MHz)  1.50-1.70 (4H, m), 2.30-2.42 (2H, m), 2.60 (2H, s), 2.60-2.70 (2H, m), 3.53 (2H, s), 
7.21-7.35 (5H, m). 
 
N-((1-Benzyl-4-hydroxypiperidin-4-yl)methyl)-2-chloroacetamide (III-4). 
To a solution of 4-(aminomethyl)-1-benzylpiperidin-4-ol (III-3) (0.50 g, 2.3 mmol) and triethylamine (3.7 ml, 
26.4 mmol) in dichloromethane (10 ml) was added 2-chloroacetyl chloride (0.22 mL, 2.7 mmol). The solution was 
stirred at rt for 10 min. 1M aqueous HCl (9 ml) was added. The solution was stirred at rt for 10 min. 1M aqueous 
NaOH (10 ml) was added and the aqueous layer was extracted with dichloromethane. The combined organic 
 54 
 
layers were dried over Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by 
amine silica gel flash chromatography (ethyl acetate-n-hexane) to afford III-4 in 64% yield. 
1
H NMR (CDCl3, 400 MHz)  1.55-1.71 (4H, m), 2.31-2.40 (2H, m), 2.58-2.66 (2H, m), 3.36 (2H, d, J = 5.9 Hz), 
3.53 (2H, s), 4.08 (2H, s), 6.94 (1H, brs), 7.21-7.35 (5H, m). 
 
9-Benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (III-5). 
To a suspension of potassium tert –butoxide in THF (5.0 ml) was added 
N-((1-benzyl-4-hydroxypiperidin-4-yl)methyl)-2-chloroacetamide (III-4) (0.50 g, 1.7 mmol) in THF (5.0 ml). The 
solution was warmed up to rt and stirred for 35 min. The solvent was evaporated under reduced pressure. The 
crude product was purified by silica gel flash chromatography (methanol/chloroform) to afford III-5 in 72% yield. 
1
H NMR (CDCl3, 400 MHz)  1.65-1.70 (2H, m), 1.87-1.95 (2H, m), 2.32-2.40 (2H, m), 2.57-2.64 (2H, m), 3.24 (2H, 
d, J = 2.7 Hz), 3.53 (2H, s), 4.16 (2H, s), 7.22-7.35 (5H, m). 
MS (ESI) m/z 261 [M+H]
+
. 
 
9-Benzyl-1-oxa-4,9-diazaspiro[5.5]undecane (III-6). 
To a suspension of LiAlH4 (0.17 g, 4.6 mmol) in THF (10 ml) cooled at 0 C was added 
9-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (III-5) (0.60 g, 2.3 mmol). The solution was stirred at rt for 30 
min. The solution was refluxed for 10 min. To the solution cooled at 0 C water (0.17 ml) was added 1M aqueous 
NaOH (0.17 ml) and water (0.35 ml). The solution was stirred at 0 C for 10 min. The mixture was filtered 
through a pad of Celite. The solvent was evaporated under reduced pressure to afford III-6 in 82% yield. 
1
H NMR (CDCl3, 400 MHz)  1.49-1.55 (2H, m), 1.88-1.95 (2H, m), 2.31-2.39 (2H, m), 2.49-2.57 (2H, m), 2.69 (2H, 
s), 2.81-2.83 (2H, m), 3.51 (2H, s), 3.63-3.67 (2H, m), 7.21-7.33 (5H, m). 
 
9-Benzyl-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide (III-7-1). 
To a solution of 9-benzyl-1-oxa-4,9-diazaspiro[5.5]undecane (III-6) (2.3 g, 9.3 mmol) in chloroform (20 
ml) cooled at 0 C was added 4-(trifluoromethoxy)phenyl isocyanate (1.9 g, 9.3 mmol). The solution was
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 stirred at rt for 30 min. The solvent was evaporated under reduced pressure. The crude product was pu
rified by silica gel flash chromatography (ethyl acetate-n-hexane) to afford III-7-1 in 90% yield. 
1
H NMR (CDCl3, 400 MHz)  1.57-1.67 (2H, m), 1.83-1.92 (2H, m), 2.36-2.44 (2H, m), 2.50-2.57 (2H, m), 3.48 (2H, 
t, J = 5.1 Hz),  3.52 (2H, s), 3.76 (2H, t, J = 5.1 Hz), 6.33 (1H, s), 7.14 (2H, d, J = 8.3 Hz), 7.22-7.34 (5H, m), 7.36 
(2H, d, J = 8.3 Hz). 
MS (ESI) m/z 450 [M+H]
+
. 
 
N-(4-(Trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide (III-8-1). 
To a solution of 9-benzyl-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide 
(III-7-1) (3.8 g, 8.4 mmol) in methanol (50 ml) was added 20% Pd(OH)2 on carbon (1.8 g). Under hydr
ogen atmosphere, the mixture was stirred at rt for 16 h and filtered through a pad of Celite. The solven
t was removed under reduced pressure to afford III-8-1 in 88% yield. 
1
H NMR (CDCl3, 400 MHz)  1.47-1.57 (2H, m), 1.78-1.87 (2H, m), 1.97 (1H, brs), 2.75-2.84 (2H, m), 2.85-3.00 (2H, 
m), 3.35 (2H, s), 3.45-3.51 (4H, m), 3.77 (2H, t, J = 5.2 Hz), 6.44 (1H, s), 7.15 (2H, d, J = 9.1 Hz), 7.38 (2H, d, J = 9.1 
Hz). 
MS (ESI) m/z 360 [M+H]
+
. 
 
9-Benzyl-N-(4-(trifluoromethyl)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide (III-7-2). 
Starting from 4-(trifluoromethyl)phenyl isocyanate (1.7 g, 8.9 mmol) the title compound was obtained fol
lowing the procedure described for 9-benzyl-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undeca
ne-4-carboxamide (III-7-1) in 72% yield. 
1
H NMR (CDCl3, 400 MHz)  1.55-1.74 (2H, m), 1.85-1.93 (2H, m), 2.37-2.46 (2H, m), 2.51-2.57 (2H, m), 3.35 (2H, 
s), 3.50 (2H, t, J = 5.0 Hz),  3.53 (2H, s), 3.77 (2H, t, J = 5.0 Hz), 6.44 (1H, s), 7.22-7.33 (5H, m), 7.46 (2H, d, J = 8.8 
Hz), 7.54 (2H, d, J = 8.8 Hz). 
MS (ESI) m/z 434 [M+H]
+
. 
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9-Benzyl-N-(4-(trifluoromethyl)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide (III-8-2). 
Starting from 9-benzyl-N-(4-(trifluoromethyl)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide 
(III-7-2) (2.0 g, 4.6 mmol) the title compound was obtained following the procedure described for 
N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide (III-8-1) in 88% yield. 
1
H NMR (CDCl3, 400 MHz)  1.70-1.57 (2H, m), 1.94 (1H, brs), 1.95-2.14 (2H, m), 3.00-3.05 (4H, m), 3.42 (2H, s), 
3.49 (2H, m), 3.52 (2H, t, J = 5.0 Hz), 3.76 (2H, t, J = 5.0 Hz), 6.85 (1H, s), 7.52-7.65 (4H, m). 
 
9-(2-Fluorobenzoyl)-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide (II
I-22). 
To a solution of-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide (III-8-1) 
(1.6 g, 4.6 mmol) and triethylamine (1.9 ml, 14 mmol) in dichloromethane (15 ml) cooled at 0 C was added 
2-fluorobenzoyl chloride (0.87 g, 5.5 mmol). The solution was stirred at 0 C for 5 min. A saturated aqueous 
solution of NaHCO3 was added and the aqueous layer was extracted with dichloromethane. The combined organic 
layers were dried over Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by 
silica gel flash chromatography (ethyl acetate-n-hexane) to afford III-22 in 84% yield. 
1
H NMR (CDCl3, 400 MHz)  1.52-1.63 (2H, m), 1.82-1.91 (1H, m), 2.03-2.10 (1H, m), 3.18-3.56 (7H, m), 3.71-3.85 
(2H, m), 4.41-4.49 (1H, m), 6.66 (1H, s), 7.01-7.15 (3H, m), 7.16-7.22 (1H, m), 7.32-7.44 (4H, m). 
MS (ESI) m/z 482 [M+H]
+
. 
 
9-(5-Methylisoxazole-3-carbonyl)-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-car
boxamide (III-31). 
To a solution of-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide (III-8-1) 
(0.40 g, 1.1 mmol), 5-methylisoxazole-3-carboxylic acid (0.14 g, 1.1 mmol) and DIPEA (0.49 ml, 2.8 mmo
l) in DMF (4.2 ml) was added HATU (0.66 g, 1.7 mmol). The solution was stirred at rt for 63 h. A sat
urated aqueous solution of NaHCO3 was added and the aqueous layer was extracted with ethyl acetate. 
The combined organic layers were dried over Na2SO4, filtered and evaporated under reduced pressure. Th
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e crude product was purified by amine silica gel flash chromatography (ethyl acetate-n-hexane) to afford 
III-31 in 92% yield. 
1
H NMR (CDCl3, 400 MHz)  1.51-1.65 (2H, m), 1.94-2.08 (2H, m), 2.46 (3H, s), 3.19-3.27 (1H, m), 3.35 (2H, s), 
3.45-3.53 (3H, m), 3.74-3.84 (2H, m), 4.09-4.15 (1H, m), 4.36-4.43 (1H, m), 6.24 (1H, s), 6.50 (1H, s), 7.14 (2H, d, J = 
8.3 Hz), 7.37 (2H, d, J = 8.3 Hz). 
MS (ESI) m/z 469 [M+H]
+
. 
 
Following the procedure described for 9-(2-fluorobenzoyl)-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazasp
iro[5.5]undecane-4-carboxamide (III-22) using corresponding acyl halides or the procedure described for 9
-(5-methylisoxazole-3-carbonyl)-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxami
de (III-31) using corresponding aminoacids compounds in Table 3-6 were obtained. 
 
Table 3-6. Data of compunds. 
Compound Name 
1
H NMR (CDCl3, 400MHz) 
MS(ESI) 
[M+H]
+
 
III-23 
9-(2,6-difluorobenzoyl)-N-(4
-(trifluoromethyl)phenyl)-1-
oxa-4,9-diazaspiro[5.5]undec
ane-4-carboxamide 
1.50-1.65 (2H, m), 1.86-1.93 (1H, m), 2.08-2.16 
(1H, m), 3.20-3.62 (7H, m), 3.73-3.85 (2H, m), 
4.47-4.55 (1H, m), 6.88-6.97 (2H, m), 7.11 (1H, s), 
7.27-7.33 (1H, m), 7.45 (2H, d, J = 9.3 Hz), 7.48 
(2H, d, J = 9.3 Hz). 
484 
III-24 
9-benzoyl-N-(4-(trifluoromet
hyl)phenyl)-1-oxa-4,9-diazas
piro[5.5]undecane-4-carboxa
mide 
1.38-1.66 (2H, m), 1.81-1.89 (1H, m), 1.98-2.09 
(1H, m), 3.39-3.70 (7H, m), 3.71-3.81 (2H, m), 
4.31-4.45 (1H, m), 7.07 (1H, s), 7.35-7.51 (9H, m). 
448 
III-25 
9-(2-chlorobenzoyl)-N-(4-(tri
fluoromethyl)phenyl)-1-oxa-
4,9-diazaspiro[5.5]undecane-
4-carboxamide 
1.35-1.55 (2H, m), 1.80-1.92 (1H, m), 2.01-2.14 
(1H, m), 3.19-3.62 (7H, m), 3.71-3.85 (2H, m), 
4.39-4.53 (1H, m), 6.82 (1H, s), 7.21-7.56 (8H, m). 
482 
III-26 
9-(3-chlorobenzoyl)-N-(4-(tri
fluoromethyl)phenyl)-1-oxa-
4,9-diazaspiro[5.5]undecane-
4-carboxamide 
1.40-1.68 (2H, m), 1.84-1.97 (1H, m), 1.98-2.12 
(1H, m), 3.22-3.62 (7H, m), 3.72-3.83 (2H, m), 
4.27-4.42 (1H, m), 6.85 (1H, s), 7.21-7.41 (4H, m), 
7.45 (2H, d, J = 8.8 Hz), 7.51 (2H, d, J = 8.8 Hz). 
482 
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III-27 
9-(4-chlorobenzoyl)-N-(4-(tri
fluoromethyl)phenyl)-1-oxa-
4,9-diazaspiro[5.5]undecane-
4-carboxamide 
1.49-1.69 (2H, m), 1.82-2.13 (2H, m), 3.22-3.65 
(7H, m), 3.72-3.85 (2H, m), 4.26-4.42 (1H, m), 6.77 
(1H, s), 7.32 (2H, d, J = 8.5 Hz), 7.38 (2H, d, J = 
8.5 Hz), 7.45 (2H, d, J = 8.8 Hz), 7.52 (2H, d, J = 
8.8 Hz). 
482 
III-28 
9-(2-acetamidobenzoyl)-N-(4
-(trifluoromethyl)phenyl)-1-
oxa-4,9-diazaspiro[5.5]undec
ane-4-carboxamide 
1.42-1.65 (2H, m), 1.76-2.09 (2H, m), 2.13 (3H, s), 
3.25-3.68 (7H, m), 3.73-3.82 (2H, m), 4.12-4.45 
(1H, m), 6.74 (1H, s), 7.06-7.12 (1H, m), 7.16-7.22 
(1H, m), 7.35-7.43 (1H,  m), 7.47 (2H, d, J = 8.8 
Hz), 7.53 (2H, d, J = 8.8 Hz), 8.12-8.17 (1H, m), 
8.87 (1H, s). 
506 
III-29 
9-(4-cyanobenzoyl)-N-(4-(tri
fluoromethyl)phenyl)-1-oxa-
4,9-diazaspiro[5.5]undecane-
4-carboxamide 
1.42-1.78 (2H, m), 1.85-1.95 (1H, m), 2.02-2.11 
(1H, m), 3.25-3.55 (7H, m), 3.76-3.88 (2H, m), 
4.32-4.45 (1H, m), 6.46 (1H, s), 7.46 (2H, d, J = 8.5 
Hz), 7.50 (2H, d, J = 8.5 Hz), 7.55 (2H, d, J = 8.5 
Hz), 7.71 (2H, d, J = 8.5 Hz). 
473 
III-30 
9-(furan-2-carbonyl)-N-(4-(tr
ifluoromethyl)phenyl)-1-oxa
-4,9-diazaspiro[5.5]undecane
-4-carboxamide 
1.43-1.55 (2H, m), 1.91-2.05 (2H, m), 3.19-3.60 
(6H, m), 3.80 (2H, t, J = 4.9 Hz), 4.10-4.39 (2H, m), 
6.46 (1H, dd, J = 1.7, 3.4 Hz), 6.92 (1H, d, J = 3.4 
Hz), 7.34 (1H, s), 7.43 (1H, d, J = 1.7 Hz), 7.50 (2H, 
d, J = 9.0 Hz), 7.54 (2H, d, J = 9.0 Hz). 
438 
III-32 
9-(5-cyclopropylisoxazole-4-
carbonyl)-N-(4-(trifluoromet
hoxy)phenyl)-1-oxa-4,9-diaz
aspiro[5.5]undecane-4-carbo
xamide 
1.09-1.19 (2H, m), 1.20-1.27 (2H, m), 1.51-1.63 
(2H, m), 1.95-2.04 (2H, m), 2.22-2.29 (1H, m), 
3.21-3.61 (6H, m), 3.81 (2H, t, J = 4.8 Hz), 
4.10-4.40 (2H, m), 6.36 (1H, s), 7.16 (2H, d, J = 8.8 
Hz), 7.36 (2H, d, J = 8.8 Hz), 8.18 (1H, s). 
495 
III-34 
9-picolinoyl-N-(4-(trifluoro
methyl)phenyl)-1-oxa-4,9-di
azaspiro[5.5]undecane-4-car
boxamide 
1.53-1.68 (2H, m), 1.84-1.91 (1H, m), 2.00-2.10 
(1H, m), 3.19-3.50 (6H, m), 3.67-3.82 (3H, m), 
4.42-4.50 (1H, m), 7.05 (1H, s), 7.30-7.36 (1H, m), 
7.48 (2H, d, J = 8.8 Hz), 7.52 (2H, d, J = 8.8 Hz), 
7.57-7.62 (1H, m), 7.75-7.81 (1H, m), 8.54-8.60 
(1H, m). 
449 
III-35 
9-(4-chloropicolinoyl)-N-(4-(
trifluoromethoxy)phenyl)-1-
oxa-4,9-diazaspiro[5.5]undec
ane-4-carboxamide 
1.55-1.69 (2H, m), 1.88-1.97 (1H, m), 2.01-2.11 
(1H, m), 3.21-3.55 (6H, m), 3.65-3.83 (3H, m), 
4.36-4.44 (1H, m), 6.56 (1H, s), 7.14 (2H, d, J = 8.8 
Hz), 7.32-7.39 (3H, m), 7.62 (1H, d, J = 1.7 Hz), 
8.46 (1H, d, J = 5.4 Hz). 
499 
III-36 9-(5-methylpyrazine-2-carbo 1.52-1.69 (2H, m), 1.91-1.99 (1H, m), 2.01-2.09 480 
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nyl)-N-(4-(trifluoromethoxy)
phenyl)-1-oxa-4,9-diazaspiro
[5.5]undecane-4-carboxamid
e 
(1H, m), 2.62 (3H, s), 3.22-3.53 (6H, m), 3.72-3.84 
(3H, m), 4.40-4.49 (1H, m), 6.49 (1H, s), 7.14 (2H, 
d, J = 8.0 Hz), 7.37 (2H, d, J = 8.0 Hz), 8.39 (1H, d, 
J = 1.5 Hz), 8.80 (1H, d, J = 1.5 Hz). 
III-37 
9-(2-oxoindoline-5-carbonyl)
-N-(4-(trifluoromethoxy)phe
nyl)-1-oxa-4,9-diazaspiro[5.
5]undecane-4-carboxamide 
1.42-1.63 (2H, m), 1.79-2.01 (2H, m), 3.21-3.55 
(9H, m), 3.73-3.82 (2H, m), 4.09-4.51 (1H, m), 6.67 
(1H, s), 6.83 (1H, d, J = 8.0 Hz), 7.12 (2H, d, J = 
8.3 Hz), 7.22-7.38 (4H, m), 8.20 (1H, s). 
519 
III-38 
9-pivaloyl-N-(4-(trifluoromet
hyl)phenyl)-1-oxa-4,9-diazas
piro[5.5]undecane-4-carboxa
mide 
1.28 (9H, s), 1.43-1.56 (2H, m), 1.89-1.97 (2H, m), 
3.23-3.32 (2H, m), 3.39 (2H, s), 3.52 (2H, t, J = 5.0 
Hz), 3.79 (2H, t, J = 5.0 Hz), 4.03-4.12 (2H, m), 
6.86 (1H, s), 7.48 (2H, d, J = 8.8 Hz), 7.53 (2H, d, J 
= 8.8 Hz). 
428 
III-39 
9-(2-cyclopropylacetyl)-N-(4
-(trifluoromethyl)phenyl)-1-
oxa-4,9-diazaspiro[5.5]undec
ane-4-carboxamide 
0.11-0.19 (2H, m), 0.51-0.59 (2H, m), 0.97-1.09 
(1H, m), 1.40-1.55 (2H, m), 1.89-1.98 (2H, m), 
2.23-2.29 (2H, m), 3.01-3.11 (1H, m), 3.30-3.43 
(3H, m), 3.45-3.63 (3H, m), 3.80 (2H, t, J = 5.2 Hz), 
4.21-4.31 (1H, m), 6.87 (1H, s), 7.50 (2H, d, J = 8.8 
Hz), 7.54 (2H, d, J = 8.8 Hz). 
426 
III-41 
9-(1-phenylcyclopropanecarb
onyl)-N-(4-(trifluoromethoxy
)phenyl)-1-oxa-4,9-diazaspir
o[5.5]undecane-4-carboxami
de 
1.01-1.49 (6H, m), 1.59-1.69 (1H, m), 1.84-1.97 
(1H, m), 3.09-3.25 (2H, m), 3.28 (2H, s), 3.45 (2H, t, 
J = 5.0 Hz), 3.66-3.83 (3H, m), 4.12-4.26 (1H, m), 
6.63 (1H, s), 7.10-7.36 (9H, m). 
505 
III-42 
9-(2-(2-methoxyphenyl)acet
yl)-N-(4-(trifluoromethoxy)p
henyl)-1-oxa-4,9-diazaspiro[
5.5]undecane-4-carboxamide 
1.25-1.60 (2H, m), 1.75-1.82 (1H, m), 1.86-1.95 
(1H, m), 3.05-3.15 (1H, m), 3.26 (2H, s), 3.30-3.39 
(1H, m), 3.40-3.51 (2H, m), 3.59-3.78 (5H, m), 3.78 
(3H, s), 4.21 -4.29 (1H, m), 6.69 (1H, s), 6.82-6.86 
(1H, m), 6.85-6.76 (1H, m), 7.13 (2H, d, J = 9.0 H), 
7.09-7.16 (2H, m), 7.36 (2H, d, J = 9.0 Hz). 
509 
III-43 
9-(2-(pyridin-2-yl)acetyl)-N-
(4-(trifluoromethoxy)phenyl)
-1-oxa-4,9-diazaspiro[5.5]un
decane-4-carboxamide 
1.29-1.43 (2H, m), 1.79-1.84 (2H, m), 3.03-3.12 
(1H, m), 3.28 (2H, s), 3.36-3.52 (3H, m), 3.75 (2H, t, 
J = 5.1 Hz), 3.78-3.96 (1H, m), 3.89 (1H, d, J = 
14.6 Hz), 3.95 (1H, d, J = 14.6 Hz), 4.21-4.27 (1H, 
m), 6.73 (1H, s), 7.11-7.18 (3H, m), 7.27-7.32 (1H, 
m), 7.35-7.37 (2H, m), 7.60-7.66 (1H, m), 8.49-8.51 
(1H, m). 
479 
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9-(2-Fluorobenzoyl)-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide (II
I-11). 
To a solution of 9-benzyl-1-oxa-4,9-diazaspiro[5.5]undecane (III-6) (18 mg, 0.071 mmol) and triethylamin
e (0.015 ml, 0.11 mmol) in dichloromethane (1 ml) was added 2,6-difluorobenzoyl chloride (14 mg, 0.07
9 mmol). The solution was stirred at rt for 5 min. 1M aqueous NaOH was added and and the aqueous l
ayer was extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered 
and evaporated under reduced pressure. The crude product was purified by silica gel flash chromatograph
y (ethyl acetate-n-hexane) to afford (9-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(2,6-difluorophenyl)meth
anone (32.4 mg). To a solution of (9-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(2,6-difluorophenyl)meth
anone (32.4 mg) in methanol (1 ml) was added 20% Pd(OH)2 on carbon (10 mg). Under hydrogen atmo
sphere, the mixture was stirred at rt for 12 h and filtered through a pad of Celite. The solvent was rem
oved under reduced pressure to afford (2,6-difluorophenyl)(1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone
 (23.2 mg). To a solution of (2,6-difluorophenyl)(1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone (10.8 m
g) and triethylamine (0.008 ml, 0.058 mmol) in chloroform (1 ml) was added 4-(trifluoromethoxy)phenyl 
isocyanate (8.5 mg, 0.042 mmol). The solution was stirred at rt for 5 min. The solvent was evaporated u
nder reduced pressure. The crude product was purified by silica gel flash chromatography (methanol/chlor
oform) to afford III-11 in 3steps 37% yield. 
1
H NMR (CDCl3, 400 MHz)  1.20-1.35 (1H, m), 1.61-1.75(1H, m), 1.91-1.99 (2H, m), 3.11-3.41 (4H, m), 3.68-3.89 
(6H, m), 6.37 (0.40H, s), 6.47 (0.60H, s), 6.93-7.01 (2H, m), 7.10-7.18 (2H, m), 7.27-7.42 (4H, m). 
MS (ESI) m/z 500 [M+H]
+
. 
 
tert-Butyl 4-formylpiperidine-1-carboxylate (III-13).  
To a solution of tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (III-12) (0.50 g, 2.3 mmol) in 
dichloromethane (10 ml) cooled at 0 C was added Dess-Martin periodinane (1.1 g, 2.6 mmol). The solution was 
stirred at rt for 2 h. A aqueous solution of Na2S2O3 and a saturated aqueous solution of NaHCO3 were added. The 
 61 
 
solution was stirred at rt for 5 min. The aqueous layer was extracted with dichloromethane. The combined organic 
layers were washed with water, dried over Na2SO4, filtered and evaporated under reduced pressure. The crude 
product was purified by silica gel flash chromatography (ethyl acetate-n-hexane) to afford III-13 in 53% yield. 
1
H NMR (CDCl3, 400 MHz)  1.46 (9H, s), 1.52-1.65 (2H, m), 1.82-1.95 (2H, m), 2.93 (2H, brt, J = 10.6 Hz), 
3.98-4.11 (2H, m), 9.67 (1H, s). 
 
tert-Butyl 4-(2-cyanoethyl)-4-formylpiperidine-1-carboxylate (III-14). 
To a solution of tert-butyl 4-formylpiperidine-1-carboxylate (III-13) (0.26 g, 1.2 mmol) in 1,4-dioxane (0.50 
ml) cooled at 0 C were added acrylonitrile (88 μl, 1.3 mmol) and benzyltrimethylammonium hydroxide (20 μl, 
10 % aqueous solution). The solution was stirred at rt for 10 h. A saturated aqueous solution of NH4Cl was added. 
The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered 
and evaporated under reduced pressure. The crude product was purified by silica gel flash chromatography (ethyl 
acetate-n-hexane) to afford III-14 in 60% yield. 
1
H NMR (CDCl3, 400 MHz)  1.39-1.51 (11H, m), 1.92 (2H, t, J = 7.9 Hz), 2.26 (2H, t, J = 7.9 Hz), 3.02 (2H, brt, 
J = 10.9 Hz), 3.70-3.89 (2H, m), 9.51 (1H, s). 
 
tert-Butyl 2,9-diazaspiro[5.5]undecane-9-carboxylate (III-15). 
To a solution of tert-butyl 4-(2-cyanoethyl)-4-formylpiperidine-1-carboxylate (III-14) (0.13 g, 0.49 mmol) in 
ethanol (6.5 ml) were added 10% Pd on carbon (0.11 g) and a HCl in methanol (0.15 ml). Under hydrogen 
atmosphere, the solution was stirred at rt for 25 h and filtered through a pad of Celite. The solvent was removed 
under reduced pressure. 1M aqueous HCl was added. The aqueous layer was washed with ethyl acetate. The 
aqueous layer was neutralized with 1M aqueous NaOH and the aqueous layer was extracted with ethyl acetate. 
The combined organic layers were dried over Na2SO4, filtered and evaporated under reduced pressure to afford 
III-15 in 29% yield. 
1
H NMR (CDCl3, 400 MHz)  1.41-1.75 (17H, m), 2.63 (2H, s), 2.78 (2H, brt, J = 5.2 Hz), 2.26 (4H, brt, J = 6.0 
Hz). 
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MS (ESI) m/z 255 [M+H]
+
. 
 
tert-Butyl 2-((4-(trifluoromethoxy)phenyl)carbamoyl)-2,9-diazaspiro[5.5]undecane-9-carboxylate (III-16). 
To a solution of tert-butyl 2,9-diazaspiro[5.5]undecane-9-carboxylate (III-15) (188 mg, 0.759 mmol) wer
e added 4-(trifluoromethoxy)phenyl isocyanate (0.13 ml, 0.80 mmo) and triethylamine (120 μl, 0.87 mmo
l). The solution was stirred at rt for 5 min. The solvent was evaporated under reduced pressure. The cru
de product was purified by silica gel flash chromatography (ethyl acetate-n-hexane) to afford III-16 in 5
0% yield. 
1
H NMR (CDCl3, 400 MHz)  1.35-1.75 (17H, m), 3.11-3.52 (8H, m), 6.36 (1H, s), 7.14 (2H, d, J = 8.0 Hz), 7.36 
(2H, d, J = 8.0 Hz). 
 
9-(2,6-Difluorobenzoyl)-N-(4-(trifluoromethoxy)phenyl)-2,9-diazaspiro[5.5]undecane-2-carboxamide (III-1
8). 
To a solution of tert-butyl 2-((4-(trifluoromethoxy)phenyl)carbamoyl)-2,9-diazaspiro[5.5]undecane-9-carboxy
late (III-16) (30.5 mg, 0.0667 mmol) in dichloromethane (2 ml) cooled at 0 C was added TFA (0.50 ml).
 The solution was stirred at 0 C for 30 min. The solvent was evaporated under reduced pressure. The 
mixture was neutralized with a saturated aqueous solution of NaHCO3 and the aqueous layer was extract
ed with dichloromethane. The combined organic layers were dried over Na2SO4, filtered and evaporated 
under reduced pressure. To solution of the crude product in dichloromethane (2 ml) cooled at 0 C were
 added triethylamine (0.0702 ml, 0.504 mmol) and 2,6-difluorobenzoyl chloride (0.0151 ml, 0.121 mmol). 
The solution was stirred at 0 C for 10 min. A saturated aqueous solution of NaHCO3 and the aqueous 
layer was extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered 
and evaporated under reduced pressure. The crude product was purified by silica gel flash chromatograph
y (ethyl acetate-n-hexane) to afford III-18 in 2steps 71% yield. 
1
H NMR (CDCl3, 400 MHz)  1.36-1.73 (8H, m), 3.21 (1H, d, J = 13.2 Hz), 3.23-3.71 (6H, m), 3.80-4.04 (1H, m), 
6.52 (1H, s), 6.92 (2H, brt, J = 8.0 Hz), 7.12 (2H, d, J = 8.3 Hz), 7.28-7.38 (3H, m). 
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MS (ESI) m/z 498 [M+H]
+
. 
 
tert-Butyl 2-(2,6-difluorobenzoyl)-2,9-diazaspiro[5.5]undecane-9-carboxylate (III-19). 
Starting from tert-butyl 2,9-diazaspiro[5.5]undecane-9-carboxylate (III-15) (36.7 mg, 0.144 mmol) and 
2,6-difluorobenzoyl chloride (0.0181 ml, 0.12 mmol) the title compound was obtained following the procedure 
described for 
9-(2-fluorobenzoyl)-N-(4-(trifluoromethoxy)phenyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide (III-22) 
in 30% yield. 
1
H NMR (CDCl3, 400 MHz)  1.32-1.63 (17H, m), 2.98-3.78 (8H, m), 6.85-6.99 (2H, m), 7.29 -7.40 (1H, m). 
MS (ESI) m/z 395 [M+H]
+
. 
 
2-(2,6-Difluorobenzoyl)-N-(4-(trifluoromethoxy)phenyl)-2,9-diazaspiro[5.5]undecane-9-carboxamide (III-2
1). 
To a solution of tert-butyl 2-(2,6-difluorobenzoyl)-2,9-diazaspiro[5.5]undecane-9-carboxylate (III-19) (17.1
 mg, 0.043 mmol) in dichloromethane (1 ml) cooled at 0 C was added TFA (0.50 ml). The solution was
 stirred at 0 C for 1 h. The solvent was evaporated under reduced pressure. The mixture was neutralize
d with 1M aqueous NaOH and the aqueous layer was extracted with dichloromethane. The combined org
anic layers were dried over Na2SO4, filtered and evaporated under reduced pressure. To solution of the c
rude product in chloroform (1 ml) cooled at 0 C were added triethylamine (0.0078 ml, 0.056 mmol) an
d 4-(trifluoromethoxy)phenyl isocyanate (0.006 ml, 0.041 mmol). The solution was stirred at 0 C for 5 
min. The solvent was evaporated under reduced pressure. The crude product was purified by silica gel fl
ash chromatography (ethyl acetate-n-hexane) to afford III-21 in 2steps 76% yield. 
1
H NMR (CDCl3, 400 MHz)  1.35-1.70 (8H, m), 3.11-3.82 (8H, m) 6.50 (0.18H, s), 6.78 (0.82H, s), 6.81-6.99 
(2H, m), 7.05-7.15 (2H, m), 7.30-7.41 (3H, m). 
MS (ESI) m/z 498 [M+H]
+
. 
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Measurement of in vitro sEH inhibitory activity. 
The sEH inhibition assays were performed as described by Jones, P. D.; Wolf, N. M.; Morisseau, C.; Whetstone, 
P.; Hock, B.; Hammock, B. D.(Anal. Biochem. 2005, 343, 66.).  A solution of recombinant sEH from human or 
mouse (the enzymes were purchased from Cayman Chemical Company) or rat (the enzyme was expressed in Sf9 
insect cells using baculovirus) in buffer (BisTris–HCl, 25 mM, pH 7.0, containing 0.1 mg/ml BSA) was incubated 
with a inhibitor at room temperture for 30 min. To the resultant solution cyano(6-methoxy-naphthalen-2-yl)methyl 
trans-[(3-phenyloxiran-2-yl)methyl] carbonate (purchased from Cayman Chemical Company) was added and 
incubated at room temperture for 20-45 min. ZnSO4 was added and the resultant solution of fluorescence intensity 
(excitation filter 330 nm, emission filter 465 nm) was measured. The reduction rate of enzyme activity by 
inhibitors were calculated using the fluorescence intensity, and IC50 values were determined. In these assays IC50 
values of a representative sEH inhibitor 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA) were 3 nM 
(human), 10 nM (murine), 10 nM (rat). 
 
Protocol of Docking Studies 
The docking studies in this chapter were effected by the same method as in chapter 2. 
 65 
 
References and Notes 
 
1. Krakower, C. A.; Nicholes, B. K.; Greenspon, S. A. Proc. Soc. Exp. Biol. Med. 1978, 159, 324. 
2. Connors, R.V.; Dai, K.; Eksterowicz, J.; Fan, P.; Fisher, B.; Fu, J.; Li, K.; Li, Z.; McGee, L.R.; Sharma, R.; 
Wang, X.; McMinn, D.; Mihalic, J.; Deignan, J. PCT Int. Appl., WO 2009085185, 2009. 
3. Nassar, A.-E. F.; Kamel, A. M.; Clarimont, C. Drug Discov. Today 2004, 9, 1020.   
 66 
 
Chapter 4 
Studies on synthesis of 1-oxa-4,9-diazaspiro[5.5]undecane scaffolds 
 
Abstract: In the synthesis of III-5, which is a precursor of the 1-oxa-4,9-diazaspiro[5.5]undecane scaffold (III-6) 
described in Chapter 3, I faced a challenge dealing with the generation of by-products. I investigated the reaction 
conditions for the synthesis of III-5 and found that reaction temperature and the order of addition of reagents 
affected the yield of III-5 relative to by-products. III-5 was isolated in 72% yield by conducting the reaction at 
-78 C following a procedure where III-4 was added to a solution of t-BuOK. 
 
 67 
 
Introduction 
 
As described in Chapter 3 I discovered 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted ureas as highly 
potent soluble epoxide hydrolase inhibitors and orally active agents for treating chronic kidney diseases. The 
synthesis of the derivatives was described in Scheme 3-1 of Chapter 3. I synthesized 
1-oxa-4,9-diazaspiro[5.5]undecane and 2,9-diazaspiro[5.5]undecane scaffold III-6, a precursor of the derivatives, 
by following the procedure described in a patent
1
 (Scheme 4-1). In the synthesis of III-5, I encountered the 
problem of reaction by-products. For studies on the physiological activities of the 
1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives, several grams of material are required. In 
addition the synthesized samples must not contain any impurities such as by-products or by-product derivatives. 
Aiming to synthesize several grams of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives in 
high yield and to reduce the generation of by-products, I investigated the reaction conditions for the synthesis of 
III-5, which was the most problematic step in the synthesis of the derivatives.  
 
 
Scheme 4-1. Synthesis of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives. 
 
Results and discussion 
 
 The reaction shown in entry 1 of Table 4-1 resulted in generation of a by-product (IV-2). This result led me to 
investigate the reaction conditions in order to improve the yield of III-5 relative to by-products. Although the 
structure of IV-2 has not been determined exactly, the postulated structure of IV-2 suggested by 
1
H-NMR spectra 
is shown in the figure of Table 4-1. Running the reaction at a lower temperature reduced the generation of IV-2 
(entries 2-4). At -78 C (entry 4), the reaction proceeded slowly. IV-2 was speculated to be a dimer of III-5, so I 
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expected that diluting the reaction medium would reduce the production of IV-2. Because dilution of reaction 
media would lower the efficiency of reaction, I adopted method b (entry 5 and 6). At room temperature (entry 5), 
the generation of by-product IV-1, which was the adduct of tert-butyl alcohol and III-4 was observed. At lower 
temperature (entry 6), generation of by-product IV-1 was reduced. Despite the reduced generation of IV-2 in entry 
4, those conditions were not selected because the reproducibility was insufficient due to the low solubility of 
t-BuOK in THF. I performed the reaction following the condition shown in entry 6 and isolated III-5 in 72% yield. 
By developing these reaction conditions, I was able to prepare several grams of 
1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives. I posited that in order to increase the 
yield of III-5 and reduce the generation of by-products, the use of other bases and solvents should be investigated. 
The use of a non-nucleophilic base would prevent the generation of an adduct like IV-I. The use of other solvents 
would alter the reactivity of the alkoxide toward III-4. 
 
Table 4-1. Reaction conditions for synthesis of III-5. 
 ( , ) 
entry method
 b
 T (C) t (min.) 
ratio(mol)
a
 
III-5 IV-1 IV-2 
1 a rt 10 1 - 1 
2 a 0 10 4.6 - 1 
3 a -18 10 17 - 1 
4 a -78~rt 30 19 - 1 
5 b 0 10 1 1 - 
6 b -78~rt 30 14 1 - 
a
 Determined by 
1
H-NMR spectral analysis. 
b Method a and b are described below. 
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Summary 
 
In the synthesis of III-5, which is a precursor of the scaffold III-6, I faced a challenge dealing with the 
generation of by-products. I investigated the reaction conditions for the synthesis of III-5 and found that 
performing the reaction at lower temperature improved the yield of III-5 relative to by-products IV-1 and IV-2. 
Moreover, the order of addition of reagents had an effect in this regard. The procedure that t-BuOK was added to a 
solution of III-4 gave by-product IV-2. A procedure where III-4 was added to a solution of t-BuOK afforded 
by-product IV-1. III-5 was isolated in 72% yield by conducting the reaction at -78C and adding III-4 to a 
solution of t-BuOK. 
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Chapter 5 
Summary 
 
In this research, I was able to identify orally active soluble epoxide hydrolase (sEH) inhibitors for the treatment 
of hypertension and chronic kidney disease. 
As described in Chapter 2, I identified 2,8-diazaspiro[4.5]decane-based trisubstituted ureas as highly potent sEH 
inhibitors and orally active agents for treating hypertension. In a structure–activity relationship study of the 
left-hand side of the ureas, I found that the potent human sEH inhibitor II-21 was a poor mouse sEH inhibitor. 
Using X-ray crystal structures, I conducted docking studies of human and mouse sEHs with II-21 and found steric 
hindrance around the side chain of Phe406 in mouse sEH. On the basis of the docking study results, I adopted a 
trifluoromethoxy moiety instead of a trifluoromethyl moiety in order to prevent such steric hindrance and succeed 
in improving mouse sEH inhibitory activity. The oral administration of II-22, II-30, and II-47 at a dose of 30 
mg/kg reduced blood pressure in spontaneously hypertensive rat, but had little effect on blood pressure in the 
normotensive rat.  
 
 
In Chapter 3, I described the identification of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted ureas as 
highly potent sEH inhibitors and orally active agents for treatment of chronic kidney diseases. III-22 exhibited 
excellent inhibitory activity against sEH and excellent bioavailability, as well as a renal protective effect in a rat 
model of anti-glomerular basement membrane glomerulonephritis. These results suggest that III-22 is an orally 
active drug candidate for treatment of chronic kidney diseases. 
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Chapter 4 presents my investigation of the reaction conditions for synthesizing III-5, a precursor of 
1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted ureas, in order to prepare sufficient amounts of material 
for use in biological tests. I found that reaction temperature and the order of addition of reagents affected the yield 
of III-5. III-5 was isolated in 72% yield by conducting the reaction at -78C by a procedure where III-4 was 
added to a solution of t-BuOK. 
This research provided orally active sEH inhibitors for the treatment of hypertension with little effect on blood 
pressure and for the treatment of chronic kidney diseases. The toxicity, physical properties, and other properties of 
the derivatives should be evaluated in preclinical studies. 
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